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Abstract
Osteoarthritis (OA) is the most common joint disease and a major cause of physical
disability, however no disease modifying treatments are available. To better understand the
molecular mechanisms involved, my colleagues previously performed microarray studies on
a surgical rodent model of OA. Transforming growth factor alpha (TGFα) was identified as a
novel growth factor involved in cartilage degeneration and subsequent experiments revealed
that it induced an OA-like phenotype in articular chondrocytes. These findings lead to the
overarching hypothesis for my thesis: TGFα promotes OA.
I began by studying TGFα’s interaction with endothelin receptor A (ET(A)R) as this
signaling system is known to be involved in both aging and OA. I used in vitro cultures to
examine whether TGFα-effects were regulated by this pathway and found that TGFα
induced expression of ET(A)R at both the gene and protein level. By inhibiting ET(A)R, I
was able to partially block some deleterious TGFα effects, however, it was evident that
additional downstream targets were involved in TGFα signaling.
To examine the role of TGFα in vivo, I used the Tgfa null mouse. I first examined bone
development as developmental events are often recapitulated in disease. Tgfa null mice had a
transient growth plate phenotype characterized by an expanded hypertrophic zone and a
delay in the transition from cartilage to bone. I also observed a decrease in RANKL and
MMP13 gene expression as well as fewer osteoclasts as the cartilage/bone junction. These
data suggest that decreased matrix resorption is responsible for the persistence of the
hypertrophic zone.
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Lastly, I examined post-traumatic and aging OA models. Interestingly, I found that young
adult Tgfa null mice were protected from developing OA in the traumatic model, however
they were not protected with age. These data suggest that TGFα might be more relevant as a
therapeutic target in post-traumatic subtypes of OA but not necessarily in idiopathic disease.
Overall, these data demonstrate a novel role for TGFα in both bone development and OA.
My developmental and disease data support my hypothesis, as TGFα appears to be a major
regulator of cartilage catabolism in both systems.
Keywords
Transforming growth factor alpha, osteoarthritis, articular cartilage, endothelin receptor A,
endochondral ossification, osteoclasts, MMP13, Rankl, DMM
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Chapter 1
1

Literature Review

1.1

Skeletal Development

The skeleton distinguishes vertebrate species from invertebrate ones. It is formed from
two tissues types: cartilage (produced by chondrocytes) and bone (produced by
osteoblasts) (98). Both chondrocytes and osteoblasts are derived from a common
mesenchymal precursor referred to as the osteochondroprogenitor. There are two main
processes through which bone development occurs: endochondral ossification and
intramembranous ossification (59). Both processes begin with the recruitment of
mesenchymal precursor cells to the location where the future bone will develop (40).
Next, the mesenchymal cells form condensations via adhesion molecules and form the
template that will eventually be replaced by bone (40).
1.1.1

Intramembranous Ossification

Intramembranous ossification occurs in several areas of the body including the flat bones
of the skull (59). During this process, the condensations of mesenchymal precursor cells
differentiate directly into osteoblasts and subsequently produce bone matrix (59). Runx2
and Osx (osterix) are two transcription factors that are absolutely essential for
osteoblastogenesis as mice with null mutations for either of these genes lack osteoblasts
(74). Most bones in the body do not form directly from osteoblasts however, but rather
form through a cartilage intermediate during the process of endochondral ossification.
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1.1.2

Endochondral Ossification

Endochondral ossification is the process through which the long bones of the body grow
and develop. As opposed to intramembranous ossification, cells within the mesenchymal
condensations differentiate into chondrocytes and form a cartilaginous template that will
eventually be replaced by bone (59). Chondrogenesis itself is regulated by a number of
transcription factors, one of most important being Sox9 (sex reversal Y-related highmobility group box protein) (57). Sox9 directly regulates a number of genes critical for
chondrocyte function including Col2a1 (type II collagen) and Agc1 (aggrecan) (57). It is
also necessary for the formation of mesenchymal condensations, the expression of Runx2,
the expression of other Sox family members, as well as chondrocyte differentiation and
proliferation (4, 57).
Endochondral ossification continues when cells at the periphery of the cartilage template
become flattened, producing a boarder of perichondrium (12, 59). The perichondral cells
retain the ability to differentiate into either osteoblasts or chondrocytes (61). Next,
driven by Sox9, cells in the center of the template begin to proliferate and produce a
characteristic matrix composed of type II collagen and aggrecan (12, 59). Eventually cells
near the center of the template stop proliferating and undergo hypertrophy (12, 59). This
step of terminal differentiation is controlled by several transcription factors including
Runx2 (57). The hypertrophic chondrocytes are unique in that they produce a matrix
predominantly containing type X collagen and promote vascular invasion through
secretion of vascular endothelial growth factor (VEGF) (12, 59). They also signal to
adjacent perichondral cells through Indian hedgehog (Ihh), causing them to differentiate
into osteoblasts and form the bone collar (12). After they have secreted their matrix,
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hypertrophic chondrocytes undergo apoptosis and the blood vessels they attracted provide
osteoclasts and osteoblasts precursors that will resorb the hypertrophic matrix and lay
down true bone (12, 59, 70). The invading blood vessels require the help of degradative
enzymes such as matrix metalloproteinases 13 and 9 (MMP13 and MMP9) to break down
the horizontal septa of matrix (70). The vertical septa of cartilage matrix between rows of
terminal chondrocytes serve as a scaffold for the formation of this true bone (also known
as the primary spongiosa) (12, 59, 70). Over time, this primary bone will be remodeled to
secondary trabecular bone (12). Collectively, this area of activity at the center of the
cartilage template is referred to as the primary ossification center (59).
1.1.3

Cartilage Growth Plate

During endochondral bone growth, the chondrocytes become highly organized into
distinct zones with separate functions (Figure 1.1). The chondrocytes closest to the ends
of the bones are small, rounded, and relatively quiescent and are referred to as resting
cells (12, 59, 70). Below them, rapidly dividing chondrocytes form columns of flat, coinshaped proliferating cells and secrete type II collagen and aggrecan (12, 59, 70). When
proliferating chondrocytes exit the cell cycle, they first become pre-hypertrophic, then
terminally differentiate into hypertrophic chondrocytes. As stated above, these cells
secrete a matrix rich in type X collagen that will eventually be resorbed and replaced with
true bone (12, 59, 70). Hypertrophic chondrocytes are easily distinguishable
histologically due to their significantly increased volume (12). Collectively, this
organizational arrangement is referred to as the cartilage growth plate and one growth
plate is present on either end of a developing long bone.
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Figure 1.1 The zones of the cartilage growth plate. The cartilage growth plate is highly
organized with several distinct zones. The resting zone consists of small, round, and
relatively quiescent cells near the ends of the bone. Next is the proliferating zone, which
consists of stacks of flattened, coined-shaped cells. Once these cells stop proliferating,
they enlarge, becoming prehypertrophic before they terminally differentiate into
hypertrophic chondrocytes.
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Figure 1.1 The zones of the cartilage growth plate.
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1.1.4

PTHrP/Ihh Signaling

Bone development and growth are tightly regulated by both local factors such as
fibroblast growth factors (FGFs) and bone morphogenetic proteins (BMPs) as well as
systemic factors such as growth hormone, thyroid hormone, and vitamin D (59, 70). The
parathyroid hormone related peptide (PTHrP) and Indian hedgehog (Ihh) signaling
pathway is an example of the tight control and coordination that is involved within the
cartilage growth plate (59). During bone development, perichondral cells at the ends of
cartilage template produce PTHrP. The PTHrP receptor (PTH/PTHrP receptor) is a Gprotein coupled receptor found on the cell surface of chondrocytes, particularly prehypertrophic chondrocytes and those in the lower proliferating zone (12, 60). When
activated, the receptor signals to increase SOX9 activity and reduce RUNX2 mRNA and
protein, thus maintaining chondrocyte proliferation and inhibition the transition to
terminal differentiation (60). Once chondrocytes do stop proliferating, however, they
secrete Ihh (Indian hedgehog), which has several roles. Ihh signals to the adjacent
perichondral cells and causes them to differentiate into osteoblasts. It also increases the
synthesis of PTHrP, to accelerate the differentiation of round proliferating cells to flat,
coin-shaped proliferating cells, and increases the rate of proliferation in adjacent
chondrocytes (59-61).
1.1.5

Secondary Ossification Centre

As long bones continue to grow, secondary ossification centers form at the proximal and
distal ends. These additional ossifications centers form through a similar process as
described above: chondrocytes stop proliferating, terminally differentiate, and attract
blood vessels that will subsequently lay down new bone (59). The cartilage at the very

7

ends of bones becomes known as articular cartilage and its main function is to provide
smooth movements for diarthrodial joints.
1.1.6

Growth Plate Closure

Longitudinal growth declines as the skeleton reaches maturity. Changes in the growth
plate occur, such as decreased proliferation, decreased diameter of the hypertrophic
chondrocytes, and decreased cell density (11). In humans, the growth plate closes
following puberty and this process is primarily under the control of the sex hormone
estrogen (11).
1.2

The Skeleton

The human skeleton is a complex and dynamic structure comprised of over 200
individual elements (51). It provides support and protection for vital organs and bone
marrow, as well as attachment sites for muscles thus facilitating movement (39, 51).
Bone also has important metabolic functions as it serves as the main reservoir for calcium
and phosphate in the body (39). Throughout life, bone constantly remodels and repairs
itself thorough the coordinated activities of osteoblasts and osteoclasts, which together
are referred to as the basic multicellular unit (BMU) (39, 83).
1.2.1

Bone Matrix

Bone is a porous material containing blood vessels, cells, and a mineralized extracellular
matrix. The matrix itself is primarily composed of type I collagen fibers, calcium
containing hydroxyapatite crystals, and non-collagenous proteins such as osteocalcin
(39). There are two main types of bone found within the skeleton: cortical and trabecular
(39). Cortical bone is very dense, has a low turnover rate, and makes up approximately
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eighty percent of the skeleton (39). It is located on the outer surfaces of skeletal elements
providing strength and protection. Trabecular bone comprises the remaining twenty
percent of the skeleton by mass, but it makes up eighty percent of the skeleton by volume
(39). Trabecular bone is found within the long bones of the skeleton, and in the inner
portions of other bones including the vertebral bodies and the bones of the pelvis (39). In
contrast to cortical bone, trabecular bone is less dense and has a high turnover rate, thus
making it the primary source for metabolic responses (39).
1.2.2

Bone Remodeling

Bone remodeling occurs constantly throughout life as the skeleton responds to
mechanical loads and strains and repairs microfractures (39). The two cell types
responsible for this process are the bone-resorbing osteoclasts and the bone-forming
osteoblasts, which together are known as the basic multicellular unit (BMU). These two
cell types communicate and collaborate to carry out the three major stages of bone
remodeling: resorption, reversal, and formation (39, 92).
1.2.3

Osteoclasts

Osteoclasts are derived from hematopoietic stem cells (27, 57). Binding of RANKL
(receptor activator of nuclear factor kappa B ligand) to its receptors on pre-osteoclasts
causes their activation, fusion, and differentiation to mature multinucleated cells (27, 39).
Osteoclasts are equipped with abundant mitochondria and lysosomal enzymes that enable
them to carry out their bone-resorbing function (27, 39). The surface of the osteoclast in
contact with bone matrix is called the ruffled boarder, and it is along this surface that
osteoclasts release their digestive enzymes including tartrate resistant acid phosphatase
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(TRAP), cathepsin K, and MMP9 (27, 39). In addition to proteolytic enzymes, osteoclasts
release hydrogen ions to acidify the matrix, thus releasing inorganic components (27, 39).
1.2.4

Osteoblasts

Unlike osteoclasts, osteoblasts are derived from mesenchymal stem cells and their
differentiation is dependent on the master regulator gene Runx2 (runt-related transcription
factor 2) (57). Osteoblasts are found in clusters along the bone surface where they deposit
type I collagen along with other non-collagenous proteins including osteocalcin,
osteopontin, osteonection, bone sialoprotein, biglycan, and decorin (27, 39). Collectively,
this unmineralized matrix is termed osteoid, and it will eventually become mineralized
with the deposition of hydroxyapatite crystals (27, 39). Osteoblasts are also responsible
for regulating osteoclast differentiation through the RANKL/OPG (osteoprotegerin)
signaling axis (27).
1.2.5

RANKL/OPG Signaling Axis

RANKL is a peptide expressed on the surface of preosteoblasts and stromal cells (39). It
is a member of the TNF superfamily and in addition to cell surface expression, it can be
cleaved to a soluble form (27, 39, 92). Its receptor, RANK, is located on the surface of
osteoclast precursor cells and when activated, initiates osteoclast differentiation and
activation (39, 92). RANKL is absolutely required for osteoclastogenesis as mice lacking
RANKL fail to produce osteoclasts (75). Cells of the osteoblast lineage also produce a
soluble decoy receptor, OPG that binds to RANKL, inhibiting its ability to activate
RANK (27, 39, 92). This coupling of osteoclast and osteoblast activity produces an
efficient and coordinated process of bone remodeling.
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1.3
1.3.1

Articular Cartilage
Cartilage Classification

Cartilage is a type of connective tissue found throughout the body with various roles
depending on its location and subtype. There are three major histological classifications
of cartilage based on the predominant structural components of the extracellular matrix:
elastic, fibro-, and hyaline cartilage (22). Elastic cartilage is located in the epiglottis and
eustachian tube, and as the name suggest, contains a high proportion of elastic fibers (22).
Fibrocartilage is found in the intervertebral discs of the spine as well as the menisci of the
knee joints and has a high proportion of fibrous tissue rich in type I collagen fibers (22,
81). Hyaline cartilage forms the growth plate of long bones and provides a template that
will eventually be replaced by bone. Hyaline cartilage is also found at the ends of
diarthrodial joints forming articular cartilage, and its predominant matrix component is
type II collagen (22, 81).
1.3.2

Articular Cartilage Composition

Articular cartilage is the highly specialized tissue that covers joint surfaces, giving rise to
near frictionless, wear-resistant and efficient movements. There are two main
components of articular cartilage: the chondrocytes (the cells of articular cartilage) and
the extracellular matrix in which they reside. Articular cartilage is relatively acellular
compared to other tissues in the body, with chondrocytes comprising only about two
percent of the total cartilage volume in adults (81). Articular cartilage is avascular,
aneural, and alymphatic, and consequently the chondrocytes themselves are primarily
responsible for secreting components of the extracellular matrix and for regulating much
of its turnover (3). The vast majority of articular cartilage is comprised of the
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extracellular matrix which is rich in type II collagen, proteoglycans such as aggrecan,
hyaluronic acid, and cross-linking proteins (3). Articular cartilage is a dynamic tissue as
type II collagen provides the main structural network and tensile strength while aggrecan
attracts water providing elastic properties (3). Due to the low cell density and lack of
blood supply however, articular cartilage is limited in its ability to self-repair.
1.3.3

Zonal Organization

Articular cartilage is designed to absorb and distribute the various stresses experienced
during joint loading (55, 81). It can be divided into three major zones (superficial,
middle, and deep), each with its own unique cellular distribution and extracellular matrix
arrangement (Figure 1.2). The superficial zone is relatively thin, and contains
horizontally arranged collagen fibrils in parallel with the articular surface (55). The
chondrocytes in the superficial zone are elliptical in shape and are also found parallel to
the surface (55). These chondrocytes synthesize and secrete a protein called lubricin,
which as the name implies, helps to lubricate and maintain a smooth, frictionless
articulating surface (81). In addition, the superficial zone is crucial to the function of
articular cartilage as it is able to withstand tensile forces experienced during joint loading
(81). In the middle zone, chondrocytes are spherical in shape and are surrounded by
randomly distributed collagen fibrils (55). Proteoglycan content increases in the midzone,
and continues to increase as one moves deeper within the articular cartilage layers (81).
This is important because aggregating proteoglycans attract water molecules and provide
articular cartilage with its elastic properties (3). Proteoglycan aggregates form when
aggrecan monomers attach to a hyaluronic acid backbone via link protein (55, 81). These
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Figure 1.2 The zones of articular cartilage. The function of articular cartilage is
dependent on its zonal organization. The superficial zone consists of elongated
chondrocytes situated in parallel with the articular surface. Collagen fibrils in this zone
are also parallel to the surface. Next is the middle zone, which is characterized by
spherical chondrocytes surrounded by more randomly distributed collagen fibrils.
Beyond this lays the deep zone containing columns of chondrocytes surrounded by
collagen fibrils perpendicular to the surface. The tidemark divides the articular cartilage
from the calcified cartilage below.
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Figure 1.2 The zones of articular cartilage.
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monomers are composed of a protein core to which negatively charged
glycosaminoglycans (GAGs) such as chondroitin sulfate and keratan sulfate attach (55).
The negatively charged molecules attract and bind intercellular water which can be
essentially ‘squished out’ under compressive forces, and drawn back in after the joint has
been unloaded (3). Lastly, the deep zone contains large chondrocytes arranged in
columns and collagen fibrils here are found perpendicular to the articular surface (55).
Between the deep zone and the subchondral bone exists a layer of calcified cartilage
which contains very large chondrocytes that behave similarly to the hypertrophic
chondrocytes of the cartilage growth plate (81). These chondrocytes secrete type X
collagen that can subsequently be mineralized. The ‘tidemark’ is a histologically visible
line demarcating the articular cartilage from the underlying calcified cartilage. The
calcified cartilage is believed to provide a transition zone from cartilage to subchondral
bone (81).
1.3.4

Regional Organization

In addition to the zonal organization of the articular cartilage, the extracellular matrix is
also described based on its proximity to the chondrocytes themselves (3). The matrix
directly adjacent to the chondrocytes is called the pericellular matrix and is rich in type
VI collagen and proteoglycans (36). The interterritorial matrix occupies the largest
proportion of articular cartilage and refers to the matrix farthest from the chondrocytes
(36). As mentioned, this proportion of the matrix is comprised primarily of type II
collagen, aggrecan, and water and allows the cartilage to deal with compressive forces.
The cartilage between the pericellular and interterritorial matrix is referred to as the
territorial matrix, but currently has no specific characterization (3).
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1.3.5

Cell-Matrix Interactions

Chondrocytes are in physical contact with their pericellular environment through cell
surface receptors such as CD44 and integrins that directly bind matrix molecules (36).
These cell surface receptors provide a direct means through which chondrocytes can
interact with and to respond to their extracellular environment and mechanical stimuli. In
addition, articular chondrocytes express stretch-activated calcium channels that respond
to mechanical stimuli by modulating intracellular calcium waves. These fluxes in calcium
subsequently cause the release of growth factors and cytokines that can then signal in an
autocrine and/or paracrine manner (2, 23). Finally, the chondrocyte cytoskeleton appears
to play an important role in mediating cellular events. In all cell types, the cytoskeleton
serves as the load-bearing architecture of the cell and can be altered by various forces (5).
Several studies have indicated that disruption of the actin cytoskeleton causes
chondrocyte de-differentiation to a fibroblastic-like phenotype (16).
1.3.6

Extracellular Matrix Metabolism

Articular chondrocytes exist in an avascular, relatively hypoxic environment (33, 35).
Consequently, they are relatively metabolically inactive and have a low regenerative
capacity. Glucose is their main energy source and enters the cells via facilitated transport
(33). Glucose also serves as a precursor for the intracellular production of
glycosaminoglycans (GAGs) (33). Adult articular cartilage has a low turn over rate with
the half-life of collagen being about one hundred years and the half-life of aggrecan core
protein fractions ranging from three to twenty-four years (33). Matrix metabolism may
however be accelerated in the pericellular zone and may also vary in disease states.
Anabolic factors including transforming growth factor beta (TGFβ) and insulin-like
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growth factor-1 (IGF-1) stimulate extracellular matrix (ECM) synthesis by chondrocytes
(87). Conversely, inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor
necrosis factor alpha (TNFα) stimulate catabolic factors (i.e. matrix metalloproteinases)
and are thus associated with matrix destruction (87). In healthy cartilage there is an
overall balance between matrix synthesis and degradation (3). In the disease state of
osteoarthritis (OA) however, the balance is shifted in favour of degradation leading to
subsequent joint dysfunction.
1.4

Osteoarthritis

Osteoarthritis (OA) is a chronic degenerative joint disease characterized by joint pain,
stiffness, and eventual loss of function (93). It is the most common joint disease
worldwide and the leading cause of physical disability in industrialized nations (58, 86).
It has been reported that one in four people in their sixties and more than half of all
people over the age of eighty demonstrate radiographic signs of OA (24). Furthermore,
sixty-seven percent of women and fifty-five percent of men over the age of fifty-five
have OA of the hand (14). While advanced age is a significant risk factor for the
development of the disease, OA can be seen in all age groups (17). Individuals living
with OA experience a substantial decline in their health-related quality of life compared
to individuals without the disease (85, 97). They suffer most dramatically physically, but
also mentally, and socially (97) . Furthermore, unlike rheumatoid arthritis, no disease
modifying drugs are available for OA. Therefore, most treatments are long term and are
limited to managing symptoms (102). The immense costs associated with OA are both
direct (medications, hospitalizations) and indirect (loss of work and productivity) and
place a significant burden on our health care system and economy (15, 100). Due to the
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prevalence of OA and the disability caused by it, OA poses significant socioeconomic
challenges.
1.4.1

Etiology and Risk Factors

While OA can present in any joint in the body, it is most commonly found in the weight
bearing joints of the knees and hips as well as in the small joints of the hands (in
particular the distal interphalangeal joints) and the spine (17, 93). Although the exact
etiology of OA remains elusive, it appears to be multifactorial in nature with many
identifiable risk factors. For example, there is good evidence to show that in addition to
increasing age, female gender, obesity, joint injury, joint malalignment, and occupations
involving repetitive joint loading all contribute the development of OA (17, 104). As
well, genetics play a clear role (86, 96). Twin studies have reveal concordance rates of
60% for hip OA and 39% for knee OA based on radiological findings in identical female
twins (96). These data are independent of environmental factors. Several gene mutations
are associated with OA, some of which encode articular cartilage matrix proteins
including type II collagen (86). Other disease associated genes are expressed in bone,
skeletal muscle, the cartilage growth plate, or in multiple synovial joint tissues (86). In
reality, it is likely that genetic factors give rise to a predisposition for OA but that the
mechanical and other risk factors also contribute to disease onset and progression.
1.4.2

Classification

OA can broadly be classified into two main groups: 1) primary or idiopathic and 2)
secondary or post-traumatic (17). Primary OA refers to a disease without a definite
etiologic cause. It is possible, however, that individuals have an unknown genetic
predisposition. Primary OA is rarely found in individuals under the age of 40 (17).
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Secondary OA, on the other hand, refers to a disease state in which there is a definite
event or abnormality leading to joint degeneration. For example, joint injuries (i.e.
ligament or meniscal tears), intra-articular fractures, and congenital abnormalities (i.e. hip
dysplasia) can all result in joint degeneration (6, 17, 104). Unlike primary OA, secondary
OA is often found in younger individuals. Regardless of the classification, both forms of
OA are complex, multivariable, and affect the entire joint. While rates of progression
may be variable, subsequent disease sequelae are often indistinguishable and involve
joint pain, stiffness, and loss of function (17).
1.4.3

A Disease of the Synovial Joint

While degeneration of articular cartilage is the hallmark of OA, it is important to
remember that the disease actually affects the entire synovial joint. In addition to
progressive cartilage damage, an osteoarthritic joint often involves subchondral bone
sclerosis, synovitis (inflammation of the synovial membrane), and osteophyte formation
(bony outgrowths at the joint margin) (3, 47) (Figure 1.3).
1.4.3.1 Articular Cartilage
While articular cartilage degeneration is the defining feature of OA, a number of more
subtle changes also occur within the extracellular matrix and the chondrocytes
themselves. Cartilage degeneration often begins with fibrillations at the articular surface
which eventually penetrate into the deeper zones (80). Another early sign of osteoarthritis
is chondrocyte proliferation resulting in clustering of cells (34, 87). Early proliferation
may be a consequence of early cartilage damage that subsequently allows mitogenic
factors from other tissues such as the synovium to reach the chondrocytes (86).
Chondrocytes may also de-differentiate and lose their characteristic phenotype of type II
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collagen and aggrecan expression (78, 87). Other chondrocyte changes that have been
observed are hypertrophy, apoptosis, and autophagy although their actual contribution to
OA pathology is not quite clear (13, 87). These processes, like osteophyte formation, are
reminiscent of stages in endochondral bone development.
1.4.3.2 Synovium
The synovial membrane lines the joint capsule and contains an inner layer of
metabolically active cells called synoviocytes (3). The synoviocytes help to nourish the
avascular articular cartilage, remove cartilage breakdown products from joint space, and
produce synovial fluid proteins including lubricin and hyaluronic acid (3, 91). The
proteins help to lubricate the joint and reduce friction, thus protecting the articular
cartilage (91). Histological changes observed in OA can be seen in both early and late
stages of the disease and include synovial cell hyperplasia, inflammation (involving the
invasion of leukocytes), and capsular fibrosis (58, 91). The synoviocytes can also
contribute directly to cartilage degeneration via production of inflammatory cytokines
and catabolic enzymes (91).
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Figure 1.3 A schematic representation of a healthy and osteoarthritic joint.
Osteoarthritis (OA) is a disease that affects the entire joint. Components of the synovial
joint include articular cartilage (blue), the joint capsule (light pink), the synovium (lining
the joint capsule), and the subchondral bone (areas directly beneath the articular
cartilage). Features of OA are depicted on the right side of the joint and include
degradation of articular cartilage, inflammation of the synovium, osteophyte formation,
and subchondral bone sclerosis (dark grey).
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Figure 1.3 A schematic representation of a healthy and osteoarthritic joint.
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1.4.3.3 Subchondral Bone
OA is associated with increased subchondral bone remodeling and thickness, however
there is uncertainty as to whether this occurs in response to the disease process or
whether this is perhaps a causative factor (21, 65). Osteoarthritic subchondral bone is
associated with increased osteoblast activity and increased osteoid deposition (64). The
increase in bone volume however, is associated with abnormal collagen fibrils and
decreased mineralization (65). Animal studies have indicated that increased bone
turnover and subsequent subchondral bone thickening are predictive of OA development,
thus suggesting that bone changes precede cartilage damage (19). In addition to these
subchondral bone changes, reactivation of the secondary ossification centre causes
advancement of the cartilage tidemark in OA, effectively thinning the articular cartilage
(19, 21). Together subchondral bone sclerosis and the advancing tidemark alter the
mechanics of the joint and may potentially exacerbate cartilage damage (19, 21).
1.4.3.4 Osteophytes
Osteophytes are yet another bone-related abnormality found in osteoarthritis. These bony
outgrowths form through an endochondral process and may be an attempt to restore
stability to a degenerating joint (80, 87). In actuality, however, they may interfere with
joint function and mobility. The origin of the osteophytes is uncertain, but they may be
derived from undifferentiated cells of the perichondrium (87). The stages of osteophyte
development (differentiation, proliferation, hypertrophy) are similar to those observed
during endochondral bone growth (87).
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1.4.4

Diagnosis

Often patients with OA present to their physicians complaining of joint pain as this is the
most prevalent symptom of the disease (93). The diagnosis of OA can be made clinically
with a medical history and physical exam (44, 93). No specific tests are required. X-ray is
a simple imaging technique that can be used to confirm the diagnosis and reveal the
cardinal signs of OA: asymmetric joint space narrowing, the presence of osteophytes
(bony outgrowths), subchondral bone sclerosis, and subchondral cysts (44). The joint
space narrowing represents loss of articular cartilage at the ends of bones, thus reducing
the space between bones. It is important to note that clinical and radiographic findings do
not always match and thus lack of radiographic evidence should not exclude the
diagnosis of OA (42, 44). Furthermore, if one has radiographic changes consistent with
OA but does not experience any symptoms, a diagnosis is not warranted. The limitation
of these diagnoses is that patients are often identified very late in the disease course.
1.4.5

Treatment

Currently there is no cure for OA and unlike rheumatoid arthritis, no disease modifying
drugs are available to alter the course of the disease. Consequently, treatment options are
limited to managing symptoms such as pain and reduced joint function. Treatment
options can be divided into broad categories including non-pharmacologic,
pharmacologic, complementary and alternative, and surgical (93). Non-pharmacologic
interventions include patient education, physiotherapy, weight loss, the use of assistive
devices, and activity modification (44, 102). Pharmacologic treatments are targeted at
reducing joint pain and include the use of acetaminophen, non-steroidal antiinflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and if necessary
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opioid analgesics (93, 102). There has been inconsistent evidence for the use of
complementary and alternative treatments such as glucosamine and/or chondroitin sulfate
and accupuncture. Thus these treatments may be recommended, but should be
discontinued if no relief is experienced (102). Lastly, several surgical options are
available. Joint replacement is recommended if other treatments fail to provide
symptomatic relief or maintain joint function (102). Osteotomies (surgical alteration of
the alignment of the joint) may also be considered in young patients with clear joint
malalignment that will likely progress to OA (102).
1.4.6

Natural History

The natural progression of OA varies from person to person with some individuals
progressing rapidly and others maintaining a relative stable disease state (30, 31). Several
risk factors have been identified for the progression of joint dysfunction including
advanced age and obesity (30, 31). For the knee joint in particular, malalignment of the
tibiofemoral joint (i.e. varus or valgus alignment) as well as meniscal injuries have been
correlated with structural disease progression (30). To complicate matters however,
studies have demonstrated that symptomatic OA (joint pain and dysfunction) does not
necessarily correlate with structural OA changes found by imaging (42).
1.4.7

The Future of OA

The incidence of OA coupled with the price required to manage the disease has placed a
serious strain on our health care system and economy. As the average life expectancy
increases and while risk factors such as obesity remain prevalent among our population,
the incidence of OA is only expected to increase in the coming years (58). Furthermore,
studies have recently shown that in addition to morbidity, OA may increase mortality,
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potentially due to lack physical activity secondary to joint dysfunction and the sequelae
from long term use of medications, particularly NSAIDs (45). It is for these reasons that
a deeper understanding of OA pathology is urgently needed in order to identify effective
treatment options and ideally find ways to halt and even reverse disease progression.
1.5

Molecular Mechanisms of Cartilage Degradation

Articular cartilage degeneration is the hallmark of osteoarthritis (OA). Unlike the classic
inflammatory disease rheumatoid arthritis (RA), which involves systemic inflammation
and symmetric joint damage, the cartilage loss seen in OA is usually asymmetric.
Cartilage degeneration can be caused by an increase in catabolic factors, by a decrease in
anabolic factors, or by a combination of both. Many signaling molecules play a role in
cartilage metabolism including cytokines, growth factors, intracellular mediators,
transcription factors, and enzymes (78). Here we will highlight some of the best-studied
molecules in OA.
1.5.1

Catabolic Factors

The inflammatory mediators TNFα and IL-1β are two predominant catabolic cytokines
involved in the initiation and progression of cartilage degeneration (33, 50). While
inflammation definitely plays a role, OA is not considered to be a classical inflammatory
disease like RA as it lacks systemic inflammatory markers and the presence of
neutrophils in the synovial fluid (33). Synovitis (inflammation of the synovium) is
present in osteoarthritis however, as is cartilage inflammation at the molecular level (50,
69). TNFα, IL-1β and their specific receptors are upregulated in OA chondrocytes (43).
In osteoarthritis, elevated levels of these cytokines have been observed in a number of
joint tissues including the synovial membrane and fluid, subchondral bone, and cartilage
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(50). TNFα and IL-1β have anti-anabolic and catabolic effects as they have been shown
to reduce type II collagen, proteoglycan, and link protein synthesis and increase a number
of catabolic enzymes (50). They also stimulate the production of prostaglandins, nitric
oxide (NO) via inducible nitric oxide synthase (iNOS), and pro-inflammatory cytokines
including IL-6, IL-17, IL-18 (33, 50).
Matrix metalloproteinases (MMPs) are the main catabolic enzymes involved in the
degradation of the articular cartilage matrix during the disease state of OA. In healthy
cartilage, these enzymes are synthesized by chondrocytes at a low rate as part of normal
cartilage maintenance and turnover (43). These enzymes are secreted from the cell into
the matrix in a pro-enzyme form, where they are eventually cleaved to their active form
by other MMPs or plasmin (87). MMP activity is further regulated by tissue inhibitors of
MMPs (TIMPs) whose expression decreases in OA, thus promoting MMP activity (86).
MMP13 (collagenase-3) is likely the most important enzyme in OA as it is capable of
degrading type II collagen fibrils with the greatest efficiency (43, 87). There are however
twenty-three MMP family members, and several including MMP1 (collagenase-1),
MMP3 (stromelysin), and MMP8 (collagenase-2) have been implicated in cartilage injury
and OA (35, 43, 87).
In addition to MMPs, aggrecanases (enzymes that digest the proteoglycan aggrecan) are
critical enzymes involved in OA. In particular, two members of the ADAMTS (a
disintegrin and metalloproteinase with thrombospondin motifs) family, namely
ADAMTS-4 and ADAMTS-5, are expressed by chondrocytes in osteoarthritis and
ADAMTS-4 is synthesized in response to TNFα and IL-1β (46, 78).
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In addition to the cytokines and growth factors mentioned above, a number of other
signaling molecules have been shown to regulate ECM turnover. A great amount of focus
has shifted to the catabolic role of nitric oxide (NO) in OA pathology (89, 95). NO and
iNOS are increased in arthritic chondrocytes, and NO itself has been shown to decrease
type II collagen and proteoglycan synthesis and increase the expression of catabolic
enzymes (1). NO can also induce chondrocyte apoptosis and positively regulate the NFkB (nuclear factor kappa B) pathway. NF-kB is a transcription factor that mediates the
expression of other proinflammatory cytokines (78).
1.5.2

Anabolic Factors

TGFβ is one of the most important anabolic factors in cartilage. It signals through TGFβ
receptors and downstream Smad activation to increase type II collagen and proteoglycan
synthesis and to decrease catabolic enzyme production (43, 78). It also counteracts the
anti-anabolic and catabolic effects of IL-1β (43, 78). In aging and arthritic chondrocytes
however, the cell’s ability to respond to TGFβ is diminished, thus blunting its anabolic
potential (78).
Bone morphogenetic proteins (BMPs) are also members of the TGFβ superfamily and
activate downstream Smad signaling (43). Several BMPs are involved in articular
cartilage homeostasis. BMP-2 is upregulated in arthritic chondrocytes, possibly in an
attempt to maintain matrix integrity (78). BMP-7 which has been shown to delay OA
progression in in vivo disease models, on the other hand, is downregulated (78).
IGF-1 signals through the IGF-1 tyrosine kinase receptor to stimulate matrix secretion,
oppose matrix degradation, and promote chondrocyte survival (33, 43). Interestingly,
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IGF-1 gene expression is increased in osteoarthritic chondrocytes, however its ability to
signal is blunted by the presence of inhibitory IGF binding proteins (33, 78). Lastly,
fibroblast growth factors (FGFs) have a more complicated role in the regulation of
articular cartilage metabolism. Studies have shown that FGF-2 (also known as basic
FGF) is released from the cartilage matrix under mechanical stress and appears to have a
mitogenic effect on chondrocytes (33, 78). This mitogenic effect might be more
pathologic than anabolic as increased proliferation of chondrocytes is often associated
with a loss of chondrocyte phenotype (78). FGF-18 in contrast, has a more
straightforward role stimulating matrix synthesis in articular chondrocytes (78).
1.6
1.6.1

Signaling Pathways in Osteoarthritis
Transforming growth factor alpha

Our laboratory recently identified transforming growth factor alpha (TGFα) as a novel
growth factor involved in OA from microarray studies performed on degenerating
cartilage in surgical rodent model of the disease (7). TGFα was first discovered in
conditioned media from murine sarcoma virus-transformed fibroblastic cells (26). It was
discovered at the same time as TGFβ and thus the two molecules have similar
nomenclature despite being structurally unrelated (18, 26, 82). Due to the nature of their
discovery, TGFα and TGFβ were originally called sarcoma growth factors, but were later
more appropriately renamed transforming growth factors (82). TGFα itself is a member
of the epidermal growth factor (EGF) family and is known to play key roles in normal
growth and development. In particular, TGFα is known to be involved in cell
proliferation, migration, and differentiation (67). A variety of embryonic and adult tissues
express TGFα including the brain, skin, gastric mucosa, colon, liver and kidney (62).
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Furthermore, various tumors and immune cells such as eosinophils, monocytes,
macrophages, and neutrophils express TGFα (20, 67, 71, 99).
To better understand the role of TGFα in vivo, several mutant mouse models have been
studied. Transgenic mice overexpressing Tgfa under control of metallothionein promoter
developed epithelial hyperplasia, pancreatic metaplasia, hepatocarincoma as well as
mammary adenocarcinoma (48, 88). Tgfa null mice were also studied and main
phenotypic changes reported include wavy fur due to unorganized hair follicle
arrangement, curly whiskers, precocious eye-opening, and corneal inflammation (73).
Surprisingly, newborn mice appeared to undergo normal post-natal development despite
altered TGFα expression (48, 73, 88).
Derived from its 160 amino acid transmembrane precursor (pro-TGFα), the 50 amino
acid length TGFα must be proteolytically cleaved to its mature, soluble form (28, 68).
Both the membrane bound and soluble forms contain the characteristic EGF-like domain
that can bind to the EGF receptor (EGFR) and thereby signal in a juxtacrine or
paracrine/autocrine fashion, respectively (25, 62, 67).
1.6.2

Epidermal Growth Factor Receptor Family and Ligands

The epidermal growth factor receptor is a receptor tyrosine kinase (RTK). As an RTK,
EGFR binding results in receptor dimerization and activation of the cytoplasmic kinase
domains (67, 90). Once activated, EGFR can then stimulate a variety of downstream
signaling pathways including the ras/raf/mitogen activated kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K)/Akt, phospholipase C (PLC), and Rho GTPase
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pathways (38, 67, 90). The physiological consequences of EGFR activation are highly
ligand-and cell type-specific (38, 67, 94).
1.6.3

EGFR Signaling and Osteoarthritis

Growing evidence supports the involvement of EGFR signaling in arthritic diseases. Both
RA and OA patients express a variety of cytokines and growth factors in their synovial
membranes including IL-1β, TNF-α, and EGF (29). RA patients express higher levels of
these cytokines, highlighting quantitative differences in these joint diseases (29).
Additional studies have detected TGFα in the synovial fluid and synovial membranes of
arthritic patients, and again these levels were higher in those with RA compared to OA
(41, 63). Furthermore, TGFα has been detected in control synovium and synovial fluid,
suggesting a normal physiological role (41).
The most convincing evidence for the involvement of EGFR signaling in OA
pathogenesis comes from recent studies involving mutations in mitogen-inducible gene 6
(MIG6) (105). MIG6 (also known as RALT or Gene 33) is a cytoplasmic protein that
negatively regulates EGFR signaling through several mechanisms, including the
inhibition of receptor kinase domains of ERBB1/EGFR and ERBB2 and receptor
internalization and degradation (32, 37, 101, 103). Homozygous null mutants of the Mig6
allele were found to develop early degenerative disease in multiple joints including the
knee, ankle, and temporomandibular joints (49, 105). The Mig6 null joints had classical
arthritic features such as loss of proteoglycan content, degradation of articular cartilage,
formation of subchondral cysts, synovial hyperplasia, osteophyte formation, and
abnormal calcification (49, 105). These studies suggest that increased EGFR signaling is
sufficient to trigger spontaneous disease progression in vivo.
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In vitro studies have tried to explain the consequences of EGFR signaling in articular
cartilage itself. When treated with exogenous EGF, primary rat articular chondrocytes
show a loss of chondrocyte phenotype through altered chondrocyte morphology as well
as decreased aggrecan and type II collagen gene expression (56).
Our own in vitro studies have shown similar effects with TGFα treatment (8). In primary
articular chondrocyte cultures, TGFα decreased expression of the anabolic genes
aggrecan (Agc1) and type II collagen (Col2) while it increased gene expression of the
catabolic factors MMP13 (Mmp13) and TNFα (Tnfa) (7). In addition, TGFα altered
chondrocyte morphology and induced stress fiber formation (7). Furthermore, articular
cartilage organ cultures treated with TGFα expressed more MMP13 than controls and
also displayed other OA-like characteristics such as chondrocyte clustering (8). These
data indicate that TGFα treatment encourages OA-like phenotypic changes in
chondrocytes. Our collaborators also found that a subset of human OA patients expressed
higher than normal TGFα mRNA levels, thus establishing an important correlation
between our animal model and the human disease state (7).
After identifying the pathologic effects of TGFα in cartilage, the next logical step was to
elucidate its signaling pathways. We used pharmacological inhibitors to block
downstream EGFR pathways and found that the RhoA/ROCK pathway and the
MEK/ERK branch of the MAPK pathway mediate many TGFα effects (9). Specifically,
RhoA/ROCK inhibition blocked TGFα-induced morphologic changes to chondrocytes,
MEK/ERK inhibition blocked the down regulation of anabolic genes, and inhibition of
both pathways decreased type II collagen cleavage by MMPs (9).
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1.6.4

Endothelin Receptor and Osteoarthritis

EGFR signaling is known to overlap and interact with many other signaling systems,
including G-protein coupled receptors (GPCRs) (38). Recently, much effort has gone into
studying the interactions between EGFR and the GPCR endothelin receptor A (ET(A)R)
in cancer cells (10, 66). In articular chondrocytes specifically, it has been observed that
EGF induces ET(A)R expression as well as that of its ligand, endothelin-1 (ET-1) (76,
77). Our interest in interactions between these two signaling systems emerged firstly
from the fact that like TGFα, ET(A)R gene expression was upregulated in our rodent
model of OA (7), and secondly from the body of research implicating both systems in OA
disease progression.
ET(A)R and its twenty-one amino acid peptide ligand endothelin-1 (ET-1) are well
known for their vasoconstrictive effects on vascular smooth muscle cells as well as their
mitogenic effects in cancer cells (66, 79). ET(A)R is a GPCR coupled to the pertussis
toxin-insensitive G-protein, Gq (66). Binding of ET-1 activates Gq which in turn
stimulates several downstream pathways including the ras/raf/MAPK, PI3K/Akt, and
PLC pathways (10, 66). ET-1 is expressed in many cell types and contributes to normal
cellular processes such as vasomotor tone, proliferation, and development (66).
There is a great deal of evidence to suggest that both ET(A)R and its ligand play
important roles in chondrocyte physiology and pathology. Articular chondrocytes were
first shown to produce and release significant quantities of endothelin in 1997 (53).
Further studies using rodent articular chondrocytes showed that ET-1 production and
ET(A)R density increased with age (52, 77). This trend is significant because age is the
number one risk factor associated with OA (17). Prolonged exposure to ET-1 has also
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been shown to inhibit proteoglycan and collagen synthesis in rat articular chondrocytes
(54). These data are complemented by reports that indicate that ET-1 increases
expression of the matrix metalloproteinases MMP1 and MMP13 in human osteoarthritic
chondrocytes (72, 84). Human osteoarthritic chondrocytes also respond to ET-1 with
increased expression of inducible nitric oxide synthase (iNOS, one enzyme responsible
for NO production), as well as elevated NO production (72). Overall, endothelin
signaling appears to discourage matrix synthesis and promote degeneration in articular
cartilage.
1.7

Overall Objectives and Hypotheses:

While OA affects the entire joint, the hallmark of this disease is the degeneration of
articular cartilage. My colleagues have previously identified transforming growth factor
alpha (TGFα) as a novel growth factor involved in cartilage degeneration. In vitro
experiments showed that TGFα had profound effects on the chondrocyte phenotype,
reducing anabolic factor expression and increasing catabolic factor expression. Based on
these data, the overarching hypothesis for my thesis is that TGFα promotes OA.
1.7.1

Objective #1

To determine the relationship between TGFα and endothelin receptor A (ET(A)R)
signaling in articular cartilage.
1.7.1.1 Rationale #1
ET(A)R signaling and TGFα appear to have similar effects on articular chondrocytes.
Since both TGFα and ET(A)R are upregulated in the surgical rodent model of OA, the
potential link between TGFα and ET(A)R signaling deserves further investigation.
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1.7.1.2 Hypothesis #1
TGFα will induce ET(A)R expression, and inhibition of ET(A)R will block TGFα–
induced effects in articular cartilage.
1.7.2

Objective #2

To characterize the role of TGFα in skeletal development.
1.7.2.1 Rationale #2
TGFα and its receptor appear to be important mediators of bone development and
physiology. However, the role of TGFα in endochondral ossification and growth plate
physiology has not yet been defined. I intend to study the role of TGFα in endochondral
ossification and characterize the growth plate phenotype of Tgfa null mice. Furthermore,
since developmental events appear to be recapitulated in OA, this study may provide
further insight into the role of TGFα in the disease state.
1.7.2.2 Hypothesis #2
Tgfa null mice will experience delayed endochondral ossification.
Objective #3
To determine the role of TGFα in osteoarthritis progression in vivo.
1.7.2.3 Rationale #3
My lab has studied the effects of exogenous TGFα using articular cartilage cell culture
and organ culture models. To determine whether these findings are relevant in the in vivo
disease state, I will evaluate the role of TGFα in both a surgical and spontaneous mouse
model of OA.
1.7.2.4 Hypothesis #3
Tgfa null mice will experience delayed OA progression compared to control littermates in
both a surgical and an aging model of disease.
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Chapter 2
2

Transforming growth factor alpha induces endothelin receptor A in
osteoarthritis

This chapter has been reproduced from:
Usmani SE, Appleton CT, and Beier F. Transforming growth factor-alpha induces
endothelin receptor A expression in osteoarthritis. J Orthop Res 30: 1391-1397, 2012.
2.1

Abstract

Previously, our lab identified transforming growth factor-alpha (TGFα) as a novel factor
involved in osteoarthritis (OA) in a surgical model of the disease. In the same study, we
also observed increased transcript levels for endothelin receptor A (ET(A)R), a known
contributor to cartilage pathology. To investigate the connection between TGFα and
endothelin signaling in OA, primary articular chondrocytes and osteochondral explants
were isolated from Sprague Dawley rats and treated with vehicle or TGFα. Expression of
ET(A)R protein and its encoding gene Ednra was assessed. Chondrocytes and cartilage
explants were also treated with the endothelin receptor A/B antagonist Bosentan, in order
to determine whether TGFα effects could be blocked. TGFα induced expression of
ET(A)R protein and its encoding gene Ednra. In primary chondrocyte cultures, Bosentan
did not block TGFα responses of the anabolic genes Sox9, Agc1, and Col2a1, but reduced
the induction of Mmp13 and Ednra transcripts by TGFα. In osteochondral explants, the
inhibitor partially blocked TGFα reduction of type II collagen, as well as induction of
MMP13 and type II collagen neoepitopes. TGFα induces ET(A)R expression in articular
chondrocytes and receptor antagonism appears to block some TGFα -induced catabolic
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effects in a three-dimensional organ culture system. Thus, TGFα may be a therapeutic
target upstream of ET(A)R in OA.
2.2

Introduction

Osteoarthritis (OA) is the most prevalent disabling condition in western society and
places a serious strain on our health care system (2). Clinical symptoms such as joint
pain and decreased joint function can severely affect day to day life for patients, however
no cure exists and current treatments only address symptoms without affecting the
underlying causes (10). As a result, there is a significant need for further investigation
and understanding of OA pathology.
While OA is a multivariable disease affecting the entire joint, one defining feature is the
degeneration of articular cartilage (2). To better understand underlying pathological
mechanisms, our lab has recently established a genome-wide profile of differentially
expressed genes in degrading cartilage in a surgical rodent model of OA (5).
Interestingly, transforming growth factor alpha (TGFα) transcript levels were upregulated
in degenerating cartilage when compared to controls (5). Thus TGFα was identified as a
novel candidate growth factor involved in cartilage degradation. Further exploration
revealed that TGFα treatment had profound effects on the chondrocyte phenotype. For
example, treatment of monolayer chondrocyte cell cultures with TGFα resulted in
suppressed expression of anabolic genes including aggrecan and type II collagen while
matrix metalloproteinase 13 (MMP13) gene expression increased (6). TGFα treatment
also altered chondrocyte morphology and induced stress fibre formation in monolayer
cultures (6). Articular cartilage organ culture studies revealed that cartilage treated with
TGFα expressed more MMP13 than controls and also displayed other OA-like
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characteristics such as cell clusters (6). A subset of human OA patients was also found to
have higher than normal TGFα mRNA levels, thus establishing an important correlation
between our rodent model and the human disease state (6).
TGFα is a member of the epidermal growth factor (EGF) family and contains the
characteristic EGF-like domain which binds to the EGF receptor (16). While EGF itself
was down-regulated in our experimental OA model, EGF receptor phosphorylation was
increased, indicating receptor activation (6). Furthermore, a recent study showed that
genetically modified mice with enhanced EGFR signaling spontaneously develop OA
(32). EGFR signaling is also known to overlap and interact many other signaling systems,
including the G-protein coupled receptor (GPCR) endothelin receptor A (ET(A)R) (11).
In articular chondrocytes specifically, it has been observed that EGF induces expression
of ET(A)R as well as of its ligand, endothelin-1 (ET-1) (19, 20). Our interest in
interactions between these two signaling systems emerged firstly from the fact that, like
TGFα, ET(A)R gene expression was upregulated in our animal model of OA (5) and
secondly from the body of research implicating both systems in OA disease progression.
Previous studies have indicated that ET(A)R and its ligand play important roles in
chondrocyte physiology and pathology. Studies using rodent articular chondrocytes
showed that ET-1 production and ET(A)R density increased with age (14, 20). This trend
is significant as age is the number one risk factor associated with OA (10). Prolonged
exposure to ET-1 has also been shown to inhibit proteoglycan and collagen synthesis in
rat articular chondrocytes (15). These data are complemented by reports which indicate
that ET-1 increases expression of the matrix metalloproteinases MMP1 and MMP13 in
human osteoarthritic chondrocytes (17, 23). Human osteoarthritic chondrocytes also
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respond to ET-1 with increased expression of inducible nitric oxide synthase (iNOS), as
well as elevated nitric oxide (NO) production (17). Elevated levels of iNOS are also
characteristic in OA cartilage and studies have shown that inhibitors of iNOS can reduce
the progression of experimental OA (3, 22, 27). Recently, Kaufman et al., elegantly
demonstrated that antagonism of ET(A)R prevents articular cartilage degradation in a
surgical rat model of OA (13). In this study, we hypothesized that TGFα signals upstream
of ET(A)R and that inhibiting ET(A)R might block some of TGFα’s OA-like changes in
articular cartilage.
2.3

Materials and Methods

2.3.1

Surgical Model of Osteoarthritis

Tissues from our original surgical OA model were analyzed in this study. Weight
controlled adult male Sprague Dawley rats underwent anterior cruciate ligament
transection (ACL-T) and partial medial meniscectomy (PM) of the right knee joint or
sham surgery as described (4, 12). All animals were exercised on a rotating cylinder for
30 minutes three times a week in order to allow full flexion and extension of their knee
joints (4).
2.3.2

Histology and Immunohistochemistry

Organ culture explants were fixed overnight in 4% paraformaldehyde and then
decalcified in an EDTA solution (0.4M EDTA, 0.3N NaOH, 1.5% glycerol and pH 7.3).
Decalcification was determined by a physical end-point test. Tissues were processed,
embedded in paraffin wax, and sectioned (6 µm thick) by the Molecular Pathology
Laboratory at Robarts Research Institute (London, ON, Canada). Immunohistochemistry
(IHC) was performed by first dewaxing sections in xylene and then rehydrating through a
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series of graded ethanols ending in water. Antigen retrieval was performed in sodium
citrate pH 6.0 for cellular proteins or Proteinase K for matrix-specific proteins. Tissues
were then blocked in 5% serum and incubated with primary antibody overnight at 4oC.
Incubation with horseradish peroxidise-conjugated secondary antibody was followed by
colorimetric detection with the substrate diaminodbenzidine (DAB). Primary antibodies
used include anti-ET(A)R, -ET(B)R and -iNOS (Abcam, Cambridge, MA, USA), antitype II collagen (R&D Systems, Minneapolis, MN, USA), anti-MMP13 (Cedarlane,
Hornby, ON, Canada) and anti-type II collagen neoepitope (7, 9).
2.3.3

Cell Culture and Organ Culture Studies

All cell and organ culture reagents were purchased from Invitrogen (Burlington, Ont.,
Canada) and Sigma (Oakville, Ont., Canada) while sterile plates were purchased from
BD Falcon (Mississauga, ON, Canada). All cells and explants were maintained in a 37oC
humidified incubator at 5% CO2 and medium was changed daily.
2.3.4

Primary Articular Chondrocyte Cell Culture

Primary articular chondrocytes were isolated from the distal femoral condyles of neonatal
Sprague Dawley rats as previously described and plated at a density of 5.0 x 104 cells/cm2
(24). A 10% fetal bovine serum culture medium was prepared from a 2:3 ratio of
DMEM:F12 supplemented with 50µg/ml ascorbic acid, 0.25% L-glutamine and 0.25%
penicillin/streptomycin. Chondrocytes were serum starved for 24 hours prior to treatment
and serum free medium was used throughout the remainder of the time course.
Chondrocyte culture medium was supplemented with TGFα (final concentration 10
ng/ml) or an equal volume of vehicle (0.1% bovine serum albumin in PBS) for up to 72
hours. Culture medium was changed daily. For our endothelin inhibitor studies, cells
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were treated with vehicle, TGFα (10 ng/ml), the endothelin receptor inhibitor Bosentan
(10 µM; provided by Actelion Pharmaceuticals Ltd , Allschwil, Switzerland) or a
combination of both for 48 hours. Bosentan is a dual endothelin receptor A/B antagonist
which is clinically used for the treatment of pulmonary arterial hypertension (18).
2.3.5

E15.5 Tibia Organ Culture

Time-mated CD1 mice were purchased from Charles River Laboratory (St. Constant,
Quebec, Canada) and embryonic E15.5 tibia were dissected as previously described (1,
26). Tibiae were cultured in media containing α-MEM supplemented with ascorbic acid,
beta-glycerophosphate, bovine serum albumin, PENSTREP®, and L-glutamine. All
tissues were maintained in a 37oC humidified incubator at 5% CO2 and treated with a
range of concentrations of recombinant human TGFα (0 to 1000 ng/ml) for six days.
Culture medium was changed every other day.
2.3.6

RNA Isolation and Real-Time PCR

RNA was isolated from rat primary chondrocytes using the Qiagen RNeasy Mini Kit and
the manufacturer’s animal cell protocol (Qiagen, Mississauga, ON, Canada). Mouse
cartilage was dissected from the ends of tibia organ cultures with the aid of a Zeiss Stemi
DV4 Stereo microscope as previously described (28), samples were placed in QIAzol
solution (Qiagen, Mississauga, ON, Canada), and RNA was isolated following the
manufacturer’s protocol. Real-time PCR was performed for the genes Ednra (endothelin
receptor A), Il1b (interleukin-1 beta), Cxcr4 (chemokine (C-X-C motif) receptor 4), Tgfa
(transforming growth factor alpha), Agc1 (aggrecan), Col2a1 (type II collagen), Sox9
(Sox9), and Mmp13 (matrix metalloproteinase 13). Analysis was performed using the
Applied Biosystems 7900HT Real-Time PCR system, the TaqMan® One-step Mastermix
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Kit, and commercially available probes (Applied Biosystems, Foster City, CA, USA).
All samples were normalized to the housekeeping gene Gapdh and day zero or vehicletreated controls using the delta-delta cycle threshold (∆∆CT) method.
2.3.7

Articular Cartilage Organ Culture

Osteochondral explants were isolated from the distal femoral condyles and proximal
tibial plateaus of 4-5 month old adult male Sprague Dawley rats. Explants were then
placed in 12-well tissue culture plates and submerged in a 2% bovine serum albumin
culture medium made from alpha-minimal essential medium supplemented with 50µg/ml
ascorbic acid, 0.25% L-glutamine and 0.25% penicillin/streptomycin for 24 hours prior to
treatment. The same treatment groups described for primary chondrocyte experiments
were repeated for organ culture studies. Explants were treated daily for up to 5 days
before tissues were prepared for histology.
2.3.8

Rhodamine Phalloidin Staining

Primary chondrocyte cell cultures were isolated as described above and plated on micro
cover glasses (VWR, Mississauga, ON, Canada) in 24-well plates at a density of 1.0 x
104 cells/cm2. Cells were treated with one of four treatments: vehicle, TGFα (10 ng/ml),
Bosentan (10 µM), or both for 48 hours. Cells were then fixed, permeabilized, and
stained with rhodamine phalloidin (Cytoskeleton Inc., Denver, CO, USA) to visualize Factin and overall cell morphology.
2.3.9

Statistics

All statistical analysis was performed using GraphPad Prism software Version 4.0. Realtime data was analysed using either a one-way analysis of variance (ANOVA) with a
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Tukey’s post-test or a two-way ANOVA with a Bonferroni’s post-test. All graphs show
mean values + standard error of the mean (SEM). A minimum of three independent
groups was used in all experiments.
2.4
2.4.1

Results
ET(A)R expression increases in a surgical model of osteoarthritis

Our previous studies have shown that ET(A)R gene expression is upregulated in OAoperated animals compared to controls, as demonstrated by microarrays and validated by
real-time PCR (5). We next wanted to examine ET(A)R protein expression in histological
samples from OA- and sham-operated animals. Immunohistochemical analysis revealed
more ET(A)R signal throughout articular surfaces in OA animals compared to controls
(Figure 2.1).
2.4.2

TGFα treatment induces ET(A)R gene expression

To examine whether TGFα can induce Ednra expression, primary rat chondrocytes in
monolayer culture were treated with vehicle or TGFα (10 ng/ml) for 1 – 3 days, followed
by isolation of RNA and real-time PCR analyses. Ednra mRNA expression increased
after 2 and 3 days of TGFα treatment (Figure 2.2A). Day 2 showed about a 9-fold
increase while day 3 showed about a 6-fold increase (Figure 2.2A). In contrast, transcript
levels of several other genes known to be involved in OA or identified in our microarray,
including Tgfa itself, Il1b, and Cxcr4, did not change significantly after treatment (Figure
2.2B-D). We next wanted to determine whether TGFα-induction of Ednra was species
specific. We therefore employed the mouse E15.5 tibia organ culture system. RNA
isolated from the cartilage ends of TGFα-treated tibiae also showed an induction of
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Figure 2.1 Endothelin receptor A (ET(A)R) protein expression is upregulated in
degenerating cartilage from an experimental rodent model of osteoarthritis (OA).
Histological sections were prepared from knee joint articular cartilage of both sham and
OA operated rats 4 weeks post-surgery. Immunohistochemistry was performed with an
anti-ET(A)R primary antibody followed by secondary antibody and visualization with the
substrate DAB (brown precipitate). Nuclei were counterstained with hematoxylin (blue).
Representative images show more ET(A)R staining in OA cartilage compared to sham
cartilage. This experiment was performed on three separate trials with similar results and
one representative trial is shown.
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Figure 2.1 Endothelin receptor A (ET(A)R) protein expression is upregulated in
degenerating cartilage from an experimental rodent model of osteoarthritis (OA).
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Figure 2.2 TGFα treatment increases expression of the endothelin receptor A gene
(Ednra). Neonatal rat primary chondrocytes were treated with or without TGFα (10
ng/ml) for up to 3 days (A-D) while E15.5 CD1 mouse tibiae were treated with a range of
TGFα concentrations (0-1000 ng/ml) for 6 days (E). Real-time PCR was used to
determine gene expression relative to Gapdh and day 0 controls. Relative expression
means +SEM are shown. A) Ednra mRNA expression increased in rat primary cultures
after days 2 and 3 of treatment while expression of the genes Il1b, Cxcr4 and Tgfa did not
change significantly after treatment (B-D). Treated mouse tibiae also showed increased
levels of Ednra transcripts (n=3-4, *P<0.05).
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Figure 2.2 TGFα treatment increases expression of the endothelin receptor A gene
(Ednra).
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Ednra transcripts, although a higher dose of TGFα was required to reach significance
(Figure 2.2E).
2.4.3

TGFα treatment induces ET(A)R protein expression

To study TGFα’s effects on ET(A)R expression in a more physiological threedimensional context, articular organ culture explants were isolated from male Sprague
Dawley rats and treated with or without TGFα. Tissues were immunostained for ET(A)R
and ET(B)R and representative images from day 1 and day 5 are shown (Figure 2.3A).
Figure 2.3 reveals an increase in ET(A)R staining in TGFα-treated explants compared to
controls. No evident change in ET(B)R expression was observed between treatments and
controls (Figure 2.3A).
2.4.4

iNOS, and NF-κB expression increase with TGFα treatment

Endothelin signalling is known to activate iNOS expression (17). Tissue sections from
articular cartilage organ cultures treated with vehicle or TGFa were stained with
antibodies against iNOS and the p65 subunit of NF-κB (a transcription factor regulating
iNOS expression (21)). The TGFα-treated tissues appear to have more positively stained
cells for iNOS than controls after 5 days of treatment (Figure 2.3B). In particular,
staining extended deeper into the cartilage in TGFα-treated samples. We saw a similar
trend for NF-κB staining (Figure 2.3B).
2.4.5

Bosentan treatment does not block TGFα-induced gene changes

To address whether inhibition of endothelin receptors can block effects of TGFα on gene
expression, primary chondrocytes were treated with vehicle, TGFα, the endothelin
receptor A/B inhibitor Bosentan or both. Bosentan treatment did not block TGFα-
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Figure 2.3 Endothelin receptor A (ET(A)R) expression increases in TGFα-treated
articular cartilage explants. Tibial and femoral articular cartilage explants were isolated
from Sprague Dawley rats and cultured with or without TGFα (10 ng/ml) for up to 5
days. Histological sections were then immunostained for ET(A)R, ET(B)R, iNOS and
NF-kB (brown precipitate) and counterstained with hematoxylin (blue).

A)

Representative images show that ET(A)R expression increased after 5 days of treatment
while ET(B)R showed no change with TGFα treatment. B) TGFα-treated tissues show
more staining for both iNOS and the transcription factor NF-kB. This experiment was
performed on three separate trials with similar results and one representative trial is
shown.
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Figure 2.3 Endothelin receptor A (ET(A)R) expression increases in TGFα-treated
articular cartilage explants.
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suppression of Agc1, Col2a1, or Sox9 mRNA levels (Figure 2.4A-C); however, Bosentan
slightly decreased the induction of Ednra (Figure 2.4D) and Mmp13 (Figure 2.4E). In the
absence of TGFα, Bosentan did not induce any significant changes in chondrocyte gene
expression.
2.4.6

Bosentan treatment does not block TGFα effects on cell morphology

TGFα has been shown to alter cell shape and induce stress fiber formation in monolayer
articular chondrocyte cultures (6), in agreement with loss of a chondrocyte phenotype
(31). As in our earlier studies, TGFα induced stress fiber formation and a more elongated
cell shape in primary chondrocytes (Figure 2.5). By itself, Bosentan did not appear to
have any effects on cell morphology or actin organization (Figure 2.5). Moreover, when
Bosentan treatment was given in combination with TGFα, no major change was observed
when compared to TGFα treatment alone (Figure 2.5).
2.4.7

Bosentan treatment blocks TGFα effects on cartilage ECM turnover

After finding limited effects of endothein receptor A/B inhibition in our monolayer
articular chondrocyte model, we decided to perform inhibitor studies in the more
physiologically relevant organ culture model. Explants were cultured with vehicle,
TGFα, Bosentan or both. Tissue sections were then immunostained for type II collagen,
MMP13, and type II collagen neoepitopes that become detectable when type II collagen
is cleaved by MMP13. TGFα-treated tissues showed a decrease in overall type II collagen
staining in the extracellular matrix (ECM) (Figure 2.6A) and an increase in MMP13
staining (Figure 2.6B). Co-treatment with Bosentan appeared to reverse these catabolic
effects (Figure 2.6A,B). Furthermore, TGFα-treatment appeared to generate more type II
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Figure 2.4 Bosentan treatment does not block TGFα-effects on gene expression.
Primary articular chondrocytes were cultured with vehicle, TGFα (10 ng/ml), the
endothelin receptor A/B inhibitor Bosentan (10 µM), or a combination of both for 48
hours. RNA was isolated and real-time PCR was performed for the genes Acg1, Col2a1,
Sox9, Ednra, and Mmp13. For all genes, measurements were relative to Gapdh and
vehicle-treated controls. Bosentan and had a slight effect of induction of Ednra (D) and
Mmp13 (E). Bosentan did not have a significant effect on any other genes (A, B, C).
Relative expression means +SEM are shown. Means with different letters are
significantly different (n=4, P<0.05).
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Figure 2.4 Bosentan treatment does not block TGFα-effects on gene expression.
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Figure 2.5 Bosentan treatment does not alter TGFα effects on actin organization.
Primary articular chondrocytes were cultured and treated with vehicle, TGFα (10 ng/ml),
the endothelin receptor inhibitor A/B Bosentan (10 µM), or a combination of both for 48
hours. Cells were then fixed and stained with rhodamine phalloidin (red) in order to
visualize F-actin. Nuclei were stained with DAPI (blue). Representative images of each
treatment are shown (n=3). Bosentan does not block TGFα effects on cell morphology or
induction of stress fibers.
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Figure 2.5 Bosentan treatment does not alter TGFα effects on actin organization.
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Figure 2.6 Bosentan treatment blocks TGFα reduction of type II collagen, induction
of MMP13, and induction of type II collagen neoepitopes. Articular cartilage explants
were treated with vehicle, TGFα (10 ng/ml), the endothelin receptor A antagonist
Bosentan (10 µM), or both for 5 days. Tissues were then immunostained for type II
collagen (A), MMP13 (B), and type II collagen neoepitopes (C) (brown precipitate).
TGFα-treated tissues showed a decrease in type II collagen staining, an increase in
MMP13 staining, and an increase in type II collagen neoepitopes. Co-treatment with
TGFα and Bosentan appeared to bring expression levels back to control levels. This
experiment was performed on four separate trials with similar results and one
representative trial is shown.
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Figure 2.6 Bosentan treatment blocks TGFα reduction of type II collagen, induction of
MMP13, and induction of type II collagen neoepitopes.
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collagen neoepitopes in the ECM when compared to controls, but the combination with
Bosentan appeared to block neoepitope induction (Figure 2.6C).
2.5

Discussion

We have previously identified TGFα as a growth factor capable of inducing OA-like
phenotypic changes in articular chondrocytes. In this study, we demonstrate that TGFα
induces ET(A)R expression in articular chondrocytes at both the gene and protein level.
Furthermore, we demonstrate that TGFα-induction of the receptor occurs in both rat and
mouse models as well as in varying ages of tissue (embryonic, newborn, and four-five
month-old). This is consistent with previous findings, in which EGF was able to induce
ET(A)R expression in both young and old rats (20). In addition to EGF and TGFα, a
number of other growth factors and cytokines are known to modulate ET(A)R receptor
density in chondrocytes (20). Furthermore, the literature suggests that the ET(A)R
receptor plays a role in both aging and degenerative joint disease (14, 17, 20, 23). Thus,
TGFα induction of ET(A)R might be one way through which TGFα mediates its
deleterious effects.
To test this hypothesis, we used the dual endothelin receptor A/B inhibitor Bosentan in
combination with TGFα treatment. We found that Bosentan treatment was not sufficient
to block TGFα-effects on anabolic gene expression in monolayer culture. Bosentan did,
however, have a minor effect on Mmp13 and Ednra levels. Bosentan was also unable to
reverse TGFα-induced changes to the chondrocyte actin cytoskeleton and cell shape.
This leads us to believe that other downstream pathways might be responsible for
anabolic gene expression changes and cytoskeletal rearrangement in TGFα-treated
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chondrocytes. Previous studies done in our laboratory show that TGFα activates many
intracellular signalling pathways (7). For example, RhoA/ROCK mediates TGFαinduced morphologic changes in chondrocytes, in agreement with our previous studies
demonstrating important roles of this pathway in chondrogenesis (29, 30). The
MEK/ERK pathway mediates the down regulation of anabolic gene expression by TGFα
(7), again line with the known roles of this pathway in chondrocytes (reviewed in (8,
25)). Both Rho/ROCK and MEK/ERK pathways also regulate type II collagen cleavage
and aggrecan breakdown in articular cartilage (7).
Bosentan had a stronger effect in the three-dimensional organ culture system where
endothelin receptor A/B inhibition was able to suppress TGFα induction of the catabolic
factor MMP13 and subsequent type II collagen break down. There are some possible
explanations for the differences observed in our two experimental systems. Firstly, age
may play a role: primary cells used in our studies were isolated from neonatal rats while
organ culture explants were isolated from adult rats. The baseline density of ET(A)R
receptors is known to be dependent on the age of articular chondrocytes and more ET-1 is
known to be produced in older chondrocytes (14, 20). In addition, endothelin receptor
signaling might be more important in the authentic three-dimensional context of cartilage
than in monolayer culture. Recently, Kaufman et al. showed that ET(A)R inhibition
prevented OA progression in a surgical model of the disease (13), in agreement with our
data shown here.
In our studies, we observed no effect on any parameters with Bosentan treatment alone.
While articular chondrocytes produce ET-1, it is possible that its levels are not high
enough in the in vitro environment to sufficiently stimulate ET(A)R receptors. ET-1
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mRNA levels however, did not change in the TGFα treatment groups (data not shown),
suggesting that it is the receptor density itself more so than the concentration of ligand
that is responsible for enhanced signaling.
In summary, our data show that ET(A)R expression in articular cartilage is increased in
response to both surgical induction of OA and TGFα treatment. We also demonstrate that
this pathway is only partially responsible for TGFα-induction of an OA-like phenotype,
but that ET(A)R inhibition suppresses catabolic activities in articular cartilage. Further
studies should be done to examine the potential benefit of upstream targets such at the
EGF receptor itself as well as combinations of downstream targets in OA therapy.
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Chapter 3
3

Transforming growth factor alpha controls the transition from hypertrophic
cartilage to bone during endochondral bone growth

This chapter has been reproduced from:
Usmani SE, Pest MA, Kim G, Ohora SN, Qin L, and Beier F. Transforming growth
factor alpha controls the transition from hypertrophic cartilage to bone during
endochondral bone growth. Bone 51: 131-141, 2012.
3.1

Abstract

We have recently identified transforming growth factor alpha (TGFα) as a novel growth
factor involved in the joint disease osteoarthritis. The role of TGFα in normal cartilage
and bone physiology however, has not been well defined. The objective of this study was
to determine the role of TGFα in bone development through investigation of the Tgfa
knockout mouse. The gross skeletons as well as the cartilage growth plates of Tgfa
knockout mice and their control littermates were examined during several developmental
stages ranging from newborn to ten-weeks-old. Knockout mice experienced skeletal
growth retardation and expansion of the hypertrophic zone of the growth plate. These
phenotypes were transient and spontaneously resolved by ten weeks of age. Tgfa
knockout growth plates also had fewer osteoclasts along the cartilage/bone interface.
Furthermore, knockout mice expressed less RUNX2, RANKL, and MMP13 mRNA in
their cartilage growth plates than controls. In conclusion, Tgfa knockout mice experience
a delay in bone development, specifically the conversion of hypertrophic cartilage to true
bone. The persistence of the hypertrophic zone of the growth plate appears to be
mediated by a decrease in MMP13 and RANKL expression in hypertrophic chondrocytes
and a resulting reduction in osteoclast recruitment. Overall, TGFα appears to be an
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important growth factor regulating the conversion of cartilage to bone during the process
of endochondral ossification.
3.2

Introduction

Our lab has recently identified transforming growth factor alpha (TGFα) as a novel factor
involved in the degeneration of articular cartilage during osteoarthritis (3-5).
Specifically, TGFα treatment modifies articular chondrocyte gene expression by
decreasing levels of anabolic genes such as type II collagen (Col2a1) and aggrecan
(Agc1) and increasing levels of catabolic genes such as matrix metalloproteinase 13
(Mmp13) (4). While much of our efforts have focused on TGFα’s role in joint pathology,
its role in normal bone and cartilage physiology, in particular during endochondral
ossification, needs to be understood to fully appreciate its function in disease.
Endochondral ossification is a highly regulated process that begins when mesenchymal
stem cells condense and differentiate into chondrocytes, providing an initial cartilage
template that will eventually be replaced by bone (26, 28). Within the condensations,
chondrocytes proliferate and secrete a characteristic matrix composed primarily of type II
collagen and aggrecan (6, 28). Cells at the centre of the condensations stop proliferating,
undergo hypertrophy, and secrete a matrix rich in type X collagen (28, 31). The
hypertrophic chondrocytes attract blood vessels, direct the mineralization of their
surrounding matrix, and ultimately undergo apoptosis (31). Osteoclasts and osteoblasts
are then recruited in order to resorb hypertrophic cartilage and to replace it with true
bone, respectively (26, 31). Eventually, secondary ossification centres form near the ends
of developing bones, and the area between the two ossification centres is known as the
cartilage growth plate (28). The growth plate consists of distinct layers, namely the
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resting zone, the proliferating zone, and the hypertrophic zone (31). Proliferation of
chondrocytes and subsequent cell enlargement during chondrocyte hypertrophy are the
main drivers of endochondral bone growth (7) .
Several studies have suggested a potential role of TGFα in early bone development.
TGFα is a member of the epidermal growth factor (EGF) family and contains the
characteristic EGF-like domain which allows it to bind to and signal through the EGF
receptor (EGFR) (29). Both TGFα and EGF negatively regulate chondrogenesis of limb
bud mesenchymal cells during embryonic development (10, 16, 51). Other studies have
examined long bone development in embryonic and neonatal EGFR null mice and found
delayed endochondral ossification, inhibited osteoclast recruitment, and an expanded
hypertrophic zone of the growth plate (49). Since EGFR null mice die soon after birth,
postnatal development could not be assessed. Another group studied the effects of
reduced EGFR signaling in older animals by creating a conditional knockin mouse
humanized for Egfr (39). These mice survived up to six months of age, experienced
growth retardation, as well as accelerated chondrocyte and osteoblast differentiation (39).
Since both of these models target the EGF receptor itself, the identity of the physiological
ligand(s) responsible for the aforementioned effects remains unknown.
TGFα has also been implicated in bone maintenance and turnover. Human recombinant
TGFα stimulates bone resorption and inhibits bone formation in vitro (17, 18). In these
studies fetal rat long bones and neonatal mouse calvariae were cultured and resorption
was assessed by calcium release while bone formation was assessed by collagen synthesis
and alkaline phosphatase activity (17, 18). These results are similar to those for EGF
treatment, but TGFα appears to be a more potent agent, inducing the same results with a
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more rapid time course (17). Tumor-derived TGFα also causes calcium release in vitro,
supporting the hypothesis that TGFα may be responsible for the increased bone
resorption and hypercalcemia seen in some malignancies (18). Additional studies have
attempted to identify the mechanisms through which TGFα mediates its effects in bone.
TGFα treatment of human marrow cultures was found to stimulate the formation of
multinucleated osteoclast-like cells by encouraging the proliferation of precursor cells
(42). Furthermore, co-cultures of osteoblastic cells and bone marrow macrophages (preosteoclasts) showed that TGFα treatment stimulates osteoclastogenesis by regulating
osteoblast production of osteoprotegerin (OPG) and monocyte chemoattractant protein 1
(MCP1, also called CCL2) (53).
TGFα and its receptor appear to be important mediators of bone development and
physiology. However, the role of TGFα in endochondral ossification and growth plate
physiology has not been clearly defined. Tgfa knockout mice were initially characterized
in 1993 and the main phenotypes reported include wavy fur, disorganized hair follicle
arrangement, curly whiskers, and corneal inflammation (32). There have been no reports
of cartilage and/or bone abnormalities. In this study, we examined the role of TGFα in
endochondral ossification and characterized the growth plate phenotype of Tgfa null
mice.
3.3
3.3.1

Materials and Methods
Materials

All cell and organ culture media reagents were purchased from Invitrogen (Burlington,
ON, Canada) and Sigma (Oakville, ON, Canada) while sterile plates were purchased
from BD Falcon (Mississauga, ON, Canada).
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3.3.2

E15.5 tibia organ culture

Time-mated CD1 mice were purchased from Charles River Laboratory (St. Constant,
Quebec, Canada). Tibiae were dissected from embryonic 15.5-day-old (E15.5) CD1 mice
and cultured in media containing α-MEM supplemented with ascorbic acid, betaglycerophosphate, bovine serum albumin, PENSTREP®, and L-glutamine as described
previously (1, 44). Tibiae were maintained in a 37oC humidified incubator at 5% CO2 and
cultured for six days. Tissues were treated with a range of concentrations of recombinant
human TGFα (0 to 1000 ng/ml) every other day. On day one and day six tibiae were
measured using a Zeiss Stemi DV4 Stereo microscope equipped with an eyepiece ruler.
Growth was determined by subtracting the length on day 1 from the length on day 6. Four
independent trials were averaged, and mean growth was analyzed using a one-way
ANOVA with Tukey’s post-tests. Whole tibiae were stained with alcian blue and alizarin
red as previously described (44). RNA was also collected from the cartilage growth plates
of these organ cultures in order to perform real-time PCR (see below).
3.3.3

Transforming growth factor alpha knockout mice

Tgfa null mice were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA).
All animals were bred and cared for in accordance with the University of Western
Ontario’s Animal Care and Use Guidelines. Heterozygous mice were crossed with each
other so that litters with all three genotypes (wild type, heterozygous, homozygous null)
could be obtained. PCR genotyping was performed using DNA from digested ear and/or
tail clippings. Two separate genotyping programs were used to amplify both the wild type
Tgfa allele and the neo-cassette found in the mutated alleles. Oligonucleotides
TGFalphaA (5’-GACTAGCCTGGGCTACACAGTG-3’) TGFalphaC (5’-
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ACATGCTGGCTTCTCTTCCTGC-3’), NeoForward (5’-CTTGGGTGGAGA
GGCTATTC-3’) and NeoReverse (5’-AGGTGAGATGACAGGAGATC-3’) were
purchased from Sigma-Aldrich (Oakville, Ont., Canada) and all other genotyping
reagents were purchased from Applied Biosystems Incorporated (Foster City, CA, USA).
Animals were sacrificed by various methods depending on age (P0- decapitation, P10intraperitoneal euthanal (pentobarbital sodium) injection, older animals- CO2 chamber).
3.3.4

Skeletal preparations

Twenty-one day old (P21) and ten-week-old wild type, heterozygous, and Tgfa null
littermates were sacrificed, eviscerated and full skeletons were stained with alizarin red
and alcian blue as previously described (48). Three sets of littermates (each containing
one wild type, one heterozygous, and one knockout mouse) were analyzed for each age
group.
3.3.5

Histology

Newborn (P0), P21, and ten-week-old littermates were sacrificed. Tibiae only were
isolated from P0 mice while tibiae and humeri were isolated from P21 and ten-week-old
mice. Tibiae and humeri were chosen because they represent long bones from the fore
and hind limbs, and also represent both proximal and distal bones. Tissues were fixed
overnight in 4% paraformaldehyde (PFA) and decalcified as required in a 5% EDTA
solution. Decalcification was not required for P0 tissues and was determined by a
physical endpoint test in older tissues. Tissues were then processed, embedded in paraffin
wax, and 5 µm thick sections were prepared by the Molecular Pathology Laboratory at
the Robarts Research Institute (London, ON, Canada).
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3.3.6

Safranin-O/fast green staining

Sections were dewaxed in xylene and rehydrated through a series of graded ethanols
ending in water. Tissues were stained in 0.02% fast green for 25 minutes, dipped in 1%
glacial acetic acid, then stained in 0.1% safranin-O for 7 minutes. Tissues were
dehydrated and coverslips were mounted using a xylene-based mounting medium.
3.3.7

Bone length and growth plate zone measurements

Prior to decalcification, the lengths of tibiae and humeri were measured using a Zeiss
Stemi DV4 Stereo microscope with eyepiece. The long bones of three sets of littermates
were measured for P21 and ten-week-old mice and data were analyzed using one-way
ANOVAs and Tukey’s post-tests.
Pictures were taken of the growth plates of P0, P21, and ten–week-old littermates using a
Retiga EX camera connected to a Leica DMRA2 microscope. Growth plate zones
(resting, proliferating, hypertrophic) were measured by a blinded observer using
OpenLab 4.0.4 software. The growth plate zones were distinguished by the unique
morphology of residing chondrocytes (resting zone - small and round, proliferating zone stacked and disc-like, hypertrophic zone - clearly enlarged), and the blinded observer had
expertise in the arrangement and organization of the growth plate. Three sets of
littermates were used for each age group and measurements were statistically analyzed
using two-way ANOVAs with Bonferroni post-tests.
3.3.8

TRAP staining and immunohistochemistry

In order to assess osteoclast number, tartrate resistant acid phosphatase (TRAP) staining
was performed on P21 tissues according to the manufacturer’s protocol with some
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modifications as previously described (43). TRAP staining was quantified in P21 tibiae
by counting the number of TRAP-positive foci along the cartilage/bone junction. An area
extending 1000 µm wide and 200 µm long (100 µm above and 100 µm below the
junction) was outlined. All positive foci within this area were included. Counts from
three independent trials were recorded and analyzed using one-way ANOVA with
Tukey’s post-tests. Immunohistochemistry was also carried out as previously described
(40, 45, 48). Primary antibody incubation occurred overnight at 4oC. Primary antibodies
included anti-platelet endothelial cell adhesion molecule 1 (PECAM-1) antibody (sc1506-R, Santa Cruz, Santa Cruz, CA, USA). Incubation with horseradish peroxidaseconjugated secondary antibody (sc-2004, Santa Cruz, Santa Cruz, CA, USA) was
followed by colorimetric detection with the substrate diaminobenzidine (DAB). For all
staining, three independent trials were used, and representative images are shown.
3.3.9

RNA isolation and real-time PCR

Growth plates were dissected from the ends of P0 tibiae and humeri with the aid of a
Zeiss Stemi DV4 Stereo microscope as previously described (48). To avoid
contamination, all surrounding connective tissue was removed and growth plates were
rinsed in sterile Puck’s Solution A. To ensure that the entire growth plate was collected,
cartilage was removed with a scalpel just above the mineralized zone. Cartilage was
clearly distinguishable from the grey area of mineralization. Alternatively, RNA was
isolated from E15.5 tibia cartilage at the end of culture as described (21, 22). Samples
were placed in QIAzol solution (Qiagen, Mississauga, ON, Canada), and RNA was
isolated following the manufacturer’s protocol. RNA was quantified and its quality was
assessed before real-time PCR was carried out as described (48, 50). Analyses were
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performed using the Applied Biosystems 7900HT Real-Time PCR system, the TaqMan®
One-step Mastermix Kit, and commercially available probes (Applied Biosystems, Foster
City, CA, USA). All samples were normalized to the housekeeping gene Gapdh and wild
type controls using the delta-delta cycle threshold (∆∆CT) method. Statistical analysis
was carried out using paired t-tests.
3.3.10

Statistical analysis

All statistical analysis was performed using GraphPad Prism software Version 4.0 and
graphs show mean values + standard error of the mean (SEM). A minimum of three
independent groups was used in all experiments.
3.4
3.4.1

Results
Human recombinant TGFα does not affect growth of E15.5 tibiae in
organ culture

E15.5 mouse tibia organ cultures were treated with and without exogenous TGFα (01000 ng/ml) for six days. Representative images show control and treated tibiae (Figure
3.1A). Length measurements at the beginning and end of culture showed no change in
overall growth over a range of TGFα concentrations (Figure 3.1B). This absence of
effects suggests that TGFα is not a major regulator of chondrocyte proliferation or
hypertrophy.
3.4.2

Tgfa null mice have shorter tibiae than their littermates

Full skeletons of male P21 wild type, heterozygous, and knockout littermates were
stained with alizarin red and alcian blue (Figure 3.2A). No gross skeletal abnormalities
were observed. However, mutant mice had significantly shorter tibiae than their wild type
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Figure 3.1 Growth of TGFα-treated tibia organ cultures. Tibiae were isolated from
E15.5 CD1 mice, grown in culture and treated with a range of TGFα concentrations.
Whole tibiae were stained with alizarin red and alcian blue at the end of culture (A).
Average growth over a six-day period was measured and is represented in millimetres
+SEM (B). There is no change in growth with any of the concentrations used (n=4).
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Figure 3.1 Growth of TGFα-treated tibia organ cultures.
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Figure 3.2 Tgfa null mice have shorter tibiae than their littermates. P21 and tenweek-old mice were sacrificed and skeletons were stained with alizarin red and alcian
blue (A, D). Mean length of P21 tibiae (B) and humeri (C) as well as ten-week-old tibiae
(E) and humeri (F) + SEM is shown. P21 knockout mice have significantly shorter tibiae
and humeri than their littermates, but no differences were seen at ten weeks of age. WT=
wild type, Het= heterozygous, KO= knockout (n=4/group, *: p<0.05).
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Figure 3.2 Tgfa null mice have shorter tibiae than their littermates.
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(8.7% reduction) and heterozygous (7.3% reduction) littermates (Figure 3.2B). Mutant
humeri were also found to be shorter than wild type and heterozygous littermates by
about 6.4% (Figure 3.2C). To determine whether this phenotype was transient or
persistent, we prepared skeletons and measured bones of ten-week-old male animals
(Figure 3.2D). There were no significant differences in the length of tibiae or humeri at
this time point (Figure 3.2E, F). Similar results were seen for female littermates (data not
shown). With the exception of P21 females, body weight was not significantly different
between genotypes (data not shown), suggesting that TGFα deficiency specifically
affects skeletal growth.
3.4.3

Tgfa null mice have expanded hypertrophic zones

In order to assess growth plate organization, growth plates from P0, P21, and ten-weekold mice were stained with safranin-O and fast green. Figure 3.3 shows representative
images and measurements from these animals. P0 and P21 Tgfa null mice have well
organized growth plates with clearly expanded hypertrophic zones (Figure 3.3A).
Measurement of growth plate zone lengths demonstrated that the hypertrophic zone, as
well as the total growth plate, were significantly longer in Tgfa null mice when compared
to their littermates, while length and organization of the resting and proliferating zones
were unchanged (Figure 3.3B, 3.3C). In contrast, ten-week-old mice showed no
differences in length of individual growth plate zones or the overall length and
organization of the growth plate (Figure 3.3A, D). Similar findings were also found in
female mice (data not shown).
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Figure 3.3. Tgfa null mice have expanded hypertrophic zones. P0 and P21 and tenweek-old tibia growth plates were stained with safranin-O and fast green (A). Growth
plate zones (RZ= resting zone, PZ = proliferating zone, HZ= hypertrophic zone) were
measured for P0 (B), P21 (C), and ten-week-old (D) animals. Mean lengths +SEM are
shown. P0 and P21 knockout mice have larger hypertrophic zones (labeled by double
arrows) and larger growth plates overall than their littermates. No change in growth plate
zones was observed at ten weeks. WT= wild type, Het= heterozygous, KO= knockout
(n=4/group, *: p<0.05).
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Figure 3.3 Tgfa null mice have expanded hypertrophic zones.
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3.4.4

Tgfa null mice have fewer osteoclasts than their littermates

Our analysis of growth plate zones did not suggest effects of TGFα deficiency on the
initiation of hypertrophy, suggesting that the larger hypertrophic zones in Tgfa null mice
might be due to delayed resorption of cartilage. In order to assess osteoclast number,
tartrate resistant acid phosphatase (TRAP) staining was performed on P21 tissues. TRAP
staining was observed in early trabecular, cortical, and subchondral bone, and differences
were observed near the growth plate/trabecular interface (Figure 3.4A). Tgfa null tissues
have diminished TRAP staining compared to their wild type and heterozygous littermates
(Figure 3.4A). The number of TRAP-positive foci was quantified along the
cartilage/bone junction, and Tgfa null mice were found to have significantly fewer
positive foci than their littermates (Figure 3.4B). Heterozygous mice also had
significantly fewer TRAP-positive foci compared to wild type mice, indicating that
TRAP expression may be dose dependent (Figure 3.4B). We also performed TRAP
staining on P0 and ten day old (P10) tissues. While we found no major differences at P0,
P10 patterns appeared similar to those of P21 showing less TRAP staining along the
growth plate/trabecular bone border in mutant animals (Supplementary Figure 3.1).
3.4.5

RUNX2, MMP13, and RANKL gene expression are decreased in Tgfa
null mice

To better understand the mechanisms at work in the mutant growth plate, we isolated
RNA from cartilage of P0 litters and performed real-time PCR on a number of genes
known to be involved in cartilage and/or bone development. In particular, we dissected
the cartilage region giving rise to the secondary ossification center to examine genes
involved in this process. We found that mRNA levels of a number of genes including
Sox9, Acan (encoding aggrecan), Col2a1 (type II collagen), Col10a1 (type X collagen),
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Figure 3.4 Tgfa null mice show reduced TRAP staining compared to their
littermates. P21 tissues were stained for the osteoclast (OC) marker tartrate resistant acid
phosphatase (TRAP, dark purple)(A). The number of TRAP-positive foci were then
quantified along the cartilage/bone interface (B). There are fewer OCs along the cartilage
growth plate/trabecular bone interface in knockout mice compared to their wild type and
heterozygous littermates. As well, there are significantly less TRAP-positive foci in the
heterozygous group compared to the wild type group. WT= wild type, Het=
heterozygous, KO= knockout (n=3/group, * : p<0.05).
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Figure 3.4 Tgfa null mice show reduced TRAP staining compared to their littermates.
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Figure 3.5 Runx2, Mmp13, and Tnfs11 expression are decreased in cartilage of Tgfa
null mice. RNA was isolated from the growth plates of long bones of P0 mice and the
expression of genes known to be involved in cartilage and bone physiology was assessed
by real-time PCR. Many genes showed no change in expression levels between
genotypes (A, B, C, E, G, I, J, K, L, M) while Runx2, Mmp13, and Tnfs11 mRNA levels
were all decreased in knockout animals (D, F, H). WT= wild type, KO = knockout
(n=4/group, *: p<0.05).
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Figure 3.5 Runx2, Mmp13, and Tnfs11 expression are decreased in cartilage of Tgfa null
mice.
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Ihh (Indian hedgehog), Tnfrs11b (encoding osteoprotegerin, OPG), Ptch1 (patched 1),
Vegfa (vascular endothelial growth factor A), Mmp9 (matrix metalloproteinase 9) and
Mmp14 (matrix metalloproteinase 14) remained unchanged between genotypes (Figure
3.5). However, expression levels of Mmp13 (matrix metalloproteinase 13), Tnfs11
(encoding receptor activator of nuclear factor kappa-B ligand, RANKL), and Runx2
(runt-related transcription factor 2) were significantly reduced in mutant animals when
compared to wild type littermates (Figure 3.5D, 3.5F, 3.5H).
3.4.6

E15.5 tibiae treated with TGFα show an increase in expression of late
hypertrophic markers

To examine whether TGFα can increase expression of those genes reduced in TGFαdeficient cartilage, RNA was collected from the growth plates of E15.5 organ cultures
treated with a range of TGFα concentrations. While no change in overall growth was
noted (Figure 3.1), real-time PCR analyses reveal changes in the expression of
hypertrophic markers. Notably, early hypertrophic markers including p57 and ColX were
decreased with TGFα treatment while late hypertrophic markers including Mmp9,
Mmp13, and Mmp14 were increased (Figure 3.6B-F). Furthermore, expression of the
RANKL gene was increased with TGFα treatment (Figure 3.6G). A number of other
genes (Sox9, Acan, Col2a1, Aft3, Runx2, Vegfa) showed no change in expression with
TGFα treatment (Supplementary Figure 3.2).
3.4.7

Tgfa null mice experience delayed secondary ossification

To analyze whether secondary ossification would be affected in a manner similar to
primary ossification, we examined the secondary ossification centers of P10 mice. Tgfa
null mice showed delayed secondary ossification when compared to both wild type and
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Figure 3.6 Early hypertrophic markers are decreased and late hypertrophic
markers are increased in TGFα-treated E15.5 tibia organ cultures. Tibiae were
isolated from E15.5 CD1 mice, grown in culture and treated with a range of TGFα
concentrations. After 6 days of treatment, RNA was isolated from the cartilage of these
tibiae (region depicted in A) and real-time PCR was performed (B-G). Data reveal
decreases in p57 and ColX, as well as increases in Mmp9, Mmp13, Mmp14, and Tnfs11
transcript levels with treatment (n=3-4/group, *: p<0.05).
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Figure 3.6 Early hypertrophic markers are decreased and late hypertrophic markers are
increased in TGFα-treated E15.5 tibia organ cultures.
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Figure 3.7 Tgfa null mice experience delayed secondary ossification and less
PECAM-1 staining. P10 long bones were isolated and stained with safranin-O and fast
green in order to observe secondary ossification centers (SOC). Knockout mice show the
persistence of hypertrophic cells and an overall delay in secondary ossification compared
to their littermates. Representative images show the SOCs of proximal humeri in the
three genotypes. P10 long bones were stained with an anti-platelet endothelial cell
adhesion molecule (PECAM-1) antibody in order to locate areas of vascularization.
Knockout mice show less PECAM-1 staining than their littermates in the secondary
ossification centers. WT= wild type, Het= heterozygous, KO= knockout (n=3).
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Figure 3.7 Tgfa null mice experience delayed secondary ossification and less PECAM-1
staining.
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heterozygous littermates (Figure 3.7). To examine vascular invasion during the formation
of secondary ossification centers, we performed IHC with an antibody against platelet
endothelial cell adhesion molecule-1 (PECAM-1), a marker of endothelial cells. We
found less PECAM-1 staining in the secondary ossification centers of knockout animals
than in those of their littermates (Figure 3.7).
We also analyzed PECAM-1 staining at the growth plate/trabecular bone interface in P0,
P10, and P21 tissues. PECAM-1 expression appeared similar among all genotypes at P0,
but mutant tissues showed reduced PECAM-1 staining at P10 and P21 (Supplementary
Figure 3.3).
3.5

Discussion

Our data show that Tgfa knockout (KO) mice have a transient growth plate and resulting
skeletal growth phenotype that appears to resolve by ten weeks of age. Phenotypic
changes include shorter tibiae and humeri, an enlarged hypertrophic zone and overall
growth plate length, delayed primary and secondary ossification, and reduced osteoclast
staining at the cartilage/bone junction.
The most dramatic aspect of this phenotype is the expanded hypertrophic zone. The
appearance of the Tgfa null hypertrophic zone is similar to that of the Egfr knockout
mouse previously described (49). However, Egfr mutants did not survive long after birth,
and consequently analyses focused on embryonic and newborn mice only (49). While we
studied post-natal time points, the resemblance between the two models is clear.
Moreover, our collaborators recently showed a similar phenotype as described here in
rats treated with an EGFR inhibitor and in mice with cartilage-specific inactivation of
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EGFR (52). Since TGFα signals through the EGFR, it is likely that TGFα the major
ligand responsible for regulating the terminal steps in endochondral ossification,
specifically the replacement of hypertrophic cartilage by bone. However, the fact that the
phenotype of Tgfa knockout mice is less severe than that of Egfr knockout mice suggests
the involvement of additional EGFR ligands in this process.
TGFα effects in our organ culture experiments (that were performed at an early stage in
skeletal development when mineralization had barely begun) are limited to markers of
later stages of hypertrophy. This finding supports the model that TGFα does not directly
control chondrocyte proliferation or early differentiation, but rather cartilage conversion
to bone tissue. In contrast to our findings, classical experiments in mesenchymal
micromass culture have indicated that TGFα is inhibitory to chondrogenesis (16). It is
possible that TGFα effects may vary depending on the extent of chondrocyte
differentiation at the start of the experiment (mesenchymal cells verses growth plate
chondrocytes) as well as on the system of study (micromass cell culture versus in vivo
and organ culture studies). Similarly, we recently showed mitogenic effects of TGFα on
articular chondrocytes (4), while both our current study and results from our collaborators
(52) suggest that TGFα does not affect growth plate chondrocyte proliferation.
In our studies, it appears that reduced osteoclast numbers are responsible for the
persistence of hypertrophic cartilage. Our data show a clear decrease in the amount of
TRAP staining at the cartilage/bone interface in mutant animals when compared to
controls. The same localized pattern of staining was observed in rats treated with an
EGFR inhibitor (52). Furthermore, RANKL gene expression is decreased in cartilage of
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our mutant animals. RANKL is a key regulator of osteoclastogenesis and is required for
bone and cartilage resorption (27). Chondrocyte-produced RANKL is able to induce
osteoclast formation (46), and RANKL-deficient mice show an expanded hypertrophic
zone similar to the one in our mice (25). A reduction in RANKL expression could
explain why we see fewer osteoclasts in Tgfa null tissues. This mechanism is biologically
plausible as previous studies have shown that TGFα signaling affects both
osteoclastogenesis and bone resorption (17, 18, 42, 53).
In addition to the Egfr knockout mouse, Mmp13 and Mmp9 mutants display expanded
hypertrophic zones, delayed vascularization, and delayed ossification (19, 41, 47).
Mmp13 null mice were also found to have abnormal TRAP and PECAM-1 staining (19).
Depending on the particular mutant studied, the abnormal growth plate phenotype was
either persistent or resolved over time (19, 41). These data are relevant since our Tgfa
null growth plate chondrocytes show decreased Mmp13 mRNA expression, in agreement
with our previous osteoarthritis studies indicating that TGFα regulates Mmp13
expression in articular chondrocytes (4, 5).
Runx2 was the third gene showing reduced expression in Tgfa knockout cartilage. Runx2
regulates terminal chondrocyte differentiation in the cartilage growth plate (20, 24) and
both Mmp13 and the RANKL gene have been identified as downstream targets (11, 23).
Thus, it seems plausible that Runx2 is the primary target of TGFα in chondrocytes and
mediates the effects of this growth factor on MMP13, RANKL and the removal of
hypertrophic cartilage.
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Interestingly, when we treated embryonic tibia organ cultures with exogenous TGFα, we
saw results that complemented our in vivo data. Specifically, we saw increases in both
MMP13 and RANKL gene expression with treatment, suggesting once again that TGFα
controls factors involved in the conversion of cartilage to bone. In the organ culture
studies, we also observed decreased expression of early hypertrophic markers (p57 and
ColX) and increased expression of late hypertrophic markers (Mmp9, Mmp13, and
Mmp14). This could suggest that TGFα promotes transition from early hypertrophic
chondrocytes to terminally differentiated cells. While ColX mRNA levels were not
changed in newborn cartilage in vivo, this difference could be due to the stages of
cartilage development analyzed in the two models or to differences between in vivo and
in vitro models.
Our knockout animals also show delayed secondary ossification and reduced staining of
the vascular marker PECAM-1. Both angiogenesis and matrix remodeling are crucial
components of the terminal events of endochondral ossification (31), and EGFR signaling
is known to have pro-angiogenic effects (2, 12, 35). TGFα specifically has been shown to
increase the expression of vascular endothelial growth factor (VEGF) and other proangiogenic factors (angiopoietin-2, G-CSF, HGF, IL-6, IL-8 and PDGF-BB) in
mesenchymal stem cells (9). Studies have shown that inactivation of VEGF leads to
decreased resorption of terminal chondrocytes, similar to what we observe in our mutant
mice (13). When examining gene expression, however, we did not see a change in Vegfa
mRNA. This leads us to believe that the observed delay in vascularization may either be
due to a reduction in other angiogenic factors or posttranscriptional suppression of VEGF
expression, or it may be secondary to reduced matrix remodeling caused by decreases in
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MMP13 and RANKL gene expression. Furthermore, it is known that MMP14 plays a
crucial role in the development of the secondary ossification centre (15). Previous studies
in our lab have shown that Akt-1 knockout mice also experience delayed secondary
ossification that appears to be mediated by MMP14 (43). We have also previously shown
that Akt-1 is a downstream target of TGFα (5). Since our tibia organ cultures indicate
that TGFα regulates MMP14 expression, this could be another mechanism by which Tgfa
mutant mice experience delayed secondary ossification.
The transient nature of the phenotype observed here might be explained by a potential
compensatory mechanism since there are multiple EGFR ligands: amphiregulin (AR),
betacellulin (BTC), EGF, epigen (EPGN), epiregulin (EREG), heparin-binding EGF-like
growth factor (HBEGF), and TGFα (14). The indication for compensation is strong since
mice lacking multiple ligands can still have subtle phenotypes. For example, triple
knockouts lacking EGF, AR, and TGFα were found to be healthy and fertile, but had
problems with mammary gland development (30). The roles of several EGFR ligands
have been investigated in bone physiology through in vivo transgenic or knockout models
(8, 36, 37), and most of these models show subtle skeletal effects (reviewed by Schneider
et. al. (38)). We examined the gene expression of AR, EGF, and HBEGF in our Tgfa wild
type and knockout mice through real-time PCR (Supplementary Figure 3.4).
Interestingly, we saw no changes in the expression levels of these ligands. There are
several possible explanations for this. Perhaps no single ligand is essential for
compensation, but rather several ligands contribute with overlapping roles. Alternatively,
regulation of the other EGFR ligands might occur post-transcriptionally. Finally, the

109

RNA we studied was from P0 mice (for technical reasons). Compensation may occur
gradually or at a later time point.
Another hypothesis to explain “catch-up growth” is delayed senescence of the growth
plate (33, 34). Potentially, mice lacking TGFα could experience a temporary decreased
growth rate that is later compensated by an increased duration of growth compared to
control animals. Nevertheless, our data demonstrate a unique, non-redundant role of
TGFα in endochondral ossification during early postnatal development.
In conclusion, our data show that Tgfa knockout mice have a hitherto unrecognized
growth plate phenotype. TGFα plays an important role in regulating endochondral
ossification, osteoclast recruitment, and vascularization at the primary and secondary
ossification center and appears to be the major ligand responsible for the observed roles
of EGFR in endochondral ossification.
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Supplementary Figure 3.1 Tgfa null mice show reduced TRAP staining along the
cartilage/bone interface. P0 and P10 tissues were stained for the osteoclast (OC) marker
tartrate resistant acid phosphatase (TRAP, dark purple). TRAP staining appears similar
amongst various genotypes in P0 tissues and is located in discrete areas throughout the
primary ossification centre (indicated by arrows). P10 knockout mice show reduced
TRAP staining along the cartilage/bone interface when compared to their control
littermates. WT= wild type, Het= heterozygous, KO= knockout (n=3).
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Supplementary 3.1 Tgfa null mice show reduced TRAP staining along the cartilage/bone
interface.
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Supplementary Figure 3.2 The expression of many genes remains unchanged in
TGFα-treated E15.5 tibia organ cultures. Tibiae were isolated from E15.5 CD1 mice,
grown in culture and treated with a range of TGFα concentrations. After 6 days of
treatment, RNA was isolated from the cartilage growth plates of these tibiae and real-time
PCR was performed. No changes in the expression of Sox9, Acan, Col2a1, Atf3, Runx2,
or Vegfa were observed (n=3-4/group, *: p<0.05).
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Supplementary 3.2 The expression of many genes remains unchanged in TGFα-treated
E15.5 tibia organ cultures.
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Supplementary Figure 3.3 Tgfa null mice show less PECAM-1 staining than their
littermates at the cartilage/bone interface. P0, P10 and P21 long bones were stained
with an anti-platelet endothelial cell adhesion molecule (PECAM-1) antibody in order to
locate areas of vascularization. PECAM-1 expression appears similar in all P0 genotypes.
P10 and P21 mutant mice show reduced PECAM-1 staining compared to their littermates
along the cartilage/bone interface. WT= wild type, Het= heterozygous, KO= knockout
(n=3).
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Supplementary 3.3 Tgfa null mice express less PECAM-1 than their littermates at the
cartilage/bone interface.

116

Supplementary Figure 3.4 Tgfa null mice do not show compensatory increases in
transcript levels for the EGFR ligands Areg, Egf, and Hbegf. RNA was isolated from
the growth plates of long bones of P0 mice and the expression of amphiregulin (Areg),
epidermal growth factor (Egf), and heparin-binding EGF-like growth factor (Hbegf) was
assessed by real-time PCR (A-C). There was no change in gene expression level for any
of the EGFR ligands examined. WT= wild type, KO = knockout (n=4/group, *: p<0.05).
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Supplementary 3.4 Tgfa null mice do not show compensatory increases in transcript
levels for the EGFR ligands Areg, Egf, and Hbegf.
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Chapter 4
4

TGFα null mice experience delayed progression of osteoarthritis in a surgical
disease model

Figures 4.2, 4.3, and 4.4 in this chapter will contribute to an original co-first author
research article to be submitted for publication:
Appleton CTG and Usmani SE, Pest MA, Pitelka V, Ulici V, Welch I, Hill TL, Mort J,
and Beier F. The TGFα-CCL2 axis is a target for treatment of osteoarthritis. To be
submitted to J Clin Invest, 2012.
4.1

Abstract

We have previously identified transforming growth factor alpha (TGFα) as a novel
growth factor involved in cartilage degeneration during the disease process of
osteoarthritis (OA). In vitro experiments show that TGFα treatment induces an OA-like
phenotype in articular chondrocytes, characterized by inhibition of matrix synthesis and
promotion of catabolic factor expression. In order to better understand and validate
TGFα’s potential as a novel therapeutic target, we employed two in vivo models of the
disease: a post-traumatic destabilization model and a spontaneous aging model. Tenweek-old male Tgfa null mice and their heterozygous (control) littermates underwent
surgery resulting in destabilization of the medial meniscus (DMM). Disease progression
was assessed histologically at both seven and fourteen weeks post-surgery using the
Osteoarthritis Research Society International (OARSI) scoring system. Six-month-old
mice also underwent the same DMM procedure and were assessed at seven weeks postsurgery. As well, spontaneous disease progression was analyzed in eighteen-month-old
Tgfa null and heterozygous mice. We found that young, ten-week old knockout mice
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were protected from OA progression at both seven and fourteen weeks post-surgery with
statistically lower OARSI scores than their control littermates. When DMM was
performed on six-month old animals however, no protection was seen. As well, no
differences were observed between genotypes in the spontaneous again model.
In conclusion, young Tgfa null mice are protected from OA progression in the DMM
model, while older mice are not. In addition, Tgfa null mice are equally susceptible to
spontaneous OA development. Thus, TGFα might be a valuable therapeutic target in
post-traumatic forms of OA, however its role in idiopathic disease less clear.
4.2

Introduction

Osteoarthritis (OA) is the most prevalent joint disease and the most common cause of
physical disability in western society (22, 39). Patients with OA experience joint pain and
impaired function that may ultimately affect their ability to work and quality of life (38,
43). Currently there are no treatment options that prevent, cure, or alter the disease
course. Rather, therapeutic options are limited to symptom management (47). The
financial consequences of managing OA are immense and relate to symptomatic
treatment, joint replacement surgeries, and work lost to disability (9, 45). Current
estimates suggest that developed nations spend approximately one to two percent of their
gross domestic product on OA and other rheumatic diseases (20). Furthermore, due to
high rates of obesity and the aging population, the incidence of OA is only expected to
rise in the coming years (22). Consequently the identification of good therapeutic targets
for the development of disease modifying osteoarthritic drugs (DMOADs) is urgently
needed.
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The defining feature of OA is the degeneration of articular cartilage – the tissue that
covers the ends of diarthrodial joints and enables their smooth, wear-resistant
movements. Articular cartilage consists of an extracellular matrix rich in type II collagen
and proteoglycans and is designed to absorb and disperse the forces experienced during
joint loading (2). The extracellular matrix is sparsely populated by chondrocytes and
these cells are responsible for both synthesizing the matrix and regulating its turnover
(35). A number of growth factors, cytokines, and catabolic enzymes are involved in
normal cartilage metabolism as well as in OA (33). As of yet however, none of the drugs
aimed at these therapeutic targets has been successful in preventing, stopping or reversing
the disease process in clinical trials (37).
While the exact etiology of OA remains unclear, numerous risk factors have been
identified (10, 49). Two of the most significant are joint injury and advanced age. It has
been well established that a history of joint injury is a major risk factor for the
development of OA (34). The causes of post-traumatic OA are vast but may involve
intra-articular fractures, ligament tears, meniscal injuries, and even cartilage microtrauma from joint impact (3). In the United States, meniscal injuries represent the highest
proportion of all intra-articular injuries (30). The menisci are crescent-shaped
fibrocartilagenous tissues found between the femur and the tibia in the medial and lateral
compartments of the knee joint (13). They help nourish and lubricate the articular
cartilage, act as shock absorbers, and transmit over half of the total axial load applied to
the knee joint (30). Studies have indicated that individuals with ligamentous or meniscal
injuries increase their risk of developing OA by ten-fold, and meniscal damage is almost
always present in patients with radiographic evidence of OA (3, 13).
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In addition to injury, advancing age is another major risk factor for OA. It is unusual to
find individuals over the age of sixty-five to seventy without radiographic evidence of
OA (26). Several theories have been developed to describe the link between aging and
OA, although there is still a lack of consensus in this area. Perhaps the simplest theory is
that OA is a “wear and tear” disease brought about by repetitive loading and an
accumulation of damage over time (1). This theory, however, does not explain why
radiographic signs are completely absent in some elderly individuals (18, 27). Other
theories relate to specific age-related changes observed in the articular cartilage matrix
and chondrocytes themselves. For example, aged cartilage undergoes more collagen
cross-linking, thus making it stiffer and perhaps more susceptible to mechanical injury
(25). As well, decreases in aggrecan deposition are seen with age, thus altering the
cartilage’s ability to deal with compressive forces (1). Aging also brings about various
changes within the chondrocytes themselves including decreased responsiveness to
anabolic cytokines such as transforming growth factor beta (TGFβ) and insulin-like
growth factor-1 (IGF-1), and increased expression of reactive oxygen species (ROS) (26).
Finally, remaining theories relate to aging and chondrocyte senescence, autophagy, and
apoptosis (1, 25, 26).
In order to better understand the molecular mechanisms involved in OA, our lab recently
studied a rodent anterior cruciate ligament (ACL) transection model to identify genes
involved in cartilage degeneration (6). We identified transforming growth factor alpha
(TGFα) as a novel growth factor involved in OA as its gene expression was increased in
the disease state. Subsequent in vitro experiments showed that TGFα treatment resulted
in a loss of chondrocyte phenotype: we observed decreases in anabolic factors including
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type II collagen and aggrecan and increases in catabolic factors such as matrix
metalloproteinase 13 (MMP13) (7). In this study, we wanted to determine the role of
TGFα in the progression of OA in vivo and thus employed a post-traumatic OA model in
the Tgfa knockout mouse. The OA model we used was the destabilization of medial
meniscus (DMM) model which provides a relatively slowly progressing form of the
disease that may have more relevance to the human disease course (16). We also
observed spontaneous development of OA in aging Tgfa null mice. Since our previous
studies suggested an overall catabolic effect of TGFα on chondrocytes, we hypothesized
that Tgfa null mice would experience delayed OA progression in both the DMM model
and in spontaneous disease development.
4.3
4.3.1

Methods
Transforming growth factor alpha null mice

Tgfa null mice in a C57BL/6 genetic background were purchased from The Jackson
Laboratory (Bar Harbor, Maine, USA) (31). All animals were bred and cared for in
accordance with the University of Western Ontario’s Animal Care and Use Guidelines.
DNA from digested ear and/or tail clippings was used in PCR genotyping. Two separate
genotyping programs were used to amplify both the wild type Tgfa allele and the neocassette found in the mutated alleles. Oligonucleotides TGFalphaA (5’GACTAGCCTGGGCTACACAGTG-3’) TGFalphaC (5’ACATGCTGGCTTCTCTTCCTGC-3’), NeoForward (5’-CTTGGGTGGAGAGGCT
ATTC-3’) and NeoReverse (5’-AGGTGAGATGACAGGAGATC-3’) were purchased
from Sigma-Aldrich (Oakville, Ont., Canada) and all other genotyping reagents were
purchased from Applied Biosystems Incorporated (Foster City, CA, USA). All direct
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comparisons were made between heterozygote and homozygote mutant siblings with at
least four littermate pairs per time point per parameter examined.
4.3.2

Destabilization of medial meniscus (DMM) model

To study OA in Tgfa mutant animals, we employed the well-established surgical
destabilization of medial meniscus (DMM) model (16). In this model, the medial
meniscotibial ligament (which anchors the medial meniscus to the tibial plateau) is
cleaved, resulting in joint destabilization. DMM was performed on the left knee joint of
ten-week old male mice as previously described (44). Both Tgfa knockout mice and their
heterozygous littermates were used in our studies. Heterozygous mice served as controls
as previous studies have shown that Tgfa heterozygous mutants are phenotypically
indistinguishable from their wild type littermates (31). Sham surgeries consisting of an
incision to the left knee were also performed on both genotypes. A veterinarian and
veterinarian technician with previous experience in the DMM procedure performed all
surgeries. Mice were housed individually after surgeries. At seven and fourteen weeks
post-surgery, mice were sacrificed and their knee joints were isolated for histology.
To examine the effects of age and injury together, we also performed DMM surgeries as
described above in six-month-old mice, and assessed disease progression at seven weeks
post-surgery.
4.3.3

Spontaneous osteoarthritis

To study the spontaneous development of OA, male and female Tgfa null mice were
housed with their heterozygous littermates until eighteen months of age. Several male
pairs were separated throughout this time course due to fighting. At eighteen months of
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age, mice were sacrificed and their knee, ankle and elbow joints were isolated and
prepared for histology.
4.3.4

Mouse tissue processing and histology

Tissues were fixed overnight in 4% PFA, and decalcified in 5% EDTA in PBS.
Decalcification was determined by physical end-point test. Tissues were then processed,
embedded in paraffin wax, and 5 µm thick serial sections were cut in the sagittal plane
starting from the medial joint compartment. Previous studies have shown that the most
severe damage in both DMM and spontaneous models of OA occur in the medial
compartment (28, 32).
4.3.5

Safranin-O/fast green staining

Sections were dewaxed in xylene and rehydrated through a series of graded ethanols
ending in water. Tissues were then stained in 0.02% fast green for 25 minutes, dipped in
1% glacial acetic acid, then stained in 0.1% safranin-O for 7 minutes. Tissues were
dehydrated and mounted using a xylene-based mounting medium.
4.3.6

Immunohistochemistry

Immunohistochemistry was performed using primary antibodies against MMP13
(Abcam, San Francisco, CA) and type II collagen neoepitopes exposed when type II
collagen is cleaved by MMP13 (8). Sections were first dewaxed in xylene, and
rehydrated through a series of graded ethanol solutions ending in water. Antigen retrieval
was performed in 10 mM sodium citrate at 95oC for fifteen minutes. Sections were
blocked in 5% goat serum, then incubated with primary antibodies overnight. Lastly,
tissues were incubated in HRP-conjugated secondary antibody and visualized with the
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substrate DAB (brown precipitate). All tissues were visualized using a Leica DM Series
inverted fluorescence/light microscope (Leica Microsystems, Richmond Hill, ON,
Canada). At least three pairs of animals were stained for each antibody and multiple
sections were used for each trial.
4.3.7

OARSI scoring for DMM

For the DMM model, two blinded observers assigned a numerical grade and stage to each
animal according to the Osteoarthritis Research Society International (OARSI) standards
for OA histopathology (36). This was the same scoring system used in our previous rat
studies (4, 5). Multiple sections were scored for each animal. One modification was made
to the scoring system: a grade of 1 was assigned if the mouse cartilage had depleted
safranin-O staining (representing depleted proteoglycan content) as this was determined
to represent significant pathology, even in the absence of cartilage discontinuity. Scores
were averaged for each group and statistical analysis was performed using a two-way
ANOVA and Bonferroni post-tests.
4.3.8

OARSI scoring for spontaneous OA

One blinded observer assigned a semi-quantitative score to each animal based on the
OARSI recommendations for histopathological assessment of OA in the mouse (17).
Again, multiple sections were used for each animal. Since this scoring system is a
variation of the one used to assess OA in the DMM model, no comparisons were made
between the DMM animals and the eighteen month old mice. Scores were averaged for
each group and statistical analysis was performed using a paired t-test.
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4.4
4.4.1

Results
Young adult Tgfa null mice experience delayed OA progression in a
DMM model

To examine the effects of Tgfa deficiency on post-traumatic OA in young adult mice,
male 10 week-old heterozygote or homozygote mutant mice underwent DMM or sham
surgery as depicted in Figure 4.1. Many disease features were apparent at the 7 week
post-surgery time point in the DMM groups including chondrocyte clustering,
hypertrophy, cell death, focal proteoglycan expression, and superficial zone fibrillation
(Figure 4.2A). This indicated that DMM induced cartilage degeneration resembling OA
pathology, as expected. The heterozygous DMM animals displayed more severe disease
features including superficial zone delamination and lesions extending into the midzone
(Figure 4.2A). All sham animals retained relatively healthy cartilage with scores below
6.0 (Figure 4.2A,B). At seven weeks post-surgery, the average OARSI score for
heterozygous DMM mice was 13.7, while the score in the sham surgery group was 5.6
(Figure 4.2B). Tgfa knockout mice that received the DMM surgery showed significantly
lower OARSI scores (average of 6.4) than their heterozygous littermates but had similar
scores to sham-operated heterozygote and homozygote mice (Figure 4.2B).
We also examined molecular markers by immunohistochemistry to further validate our
histological findings. Representative images show higher MMP13 staining in the articular
cartilage of heterozygous DMM animals than in knockout DMM animals or in sham
animals of either genotype (Figure 4.3A). Similarly, there appeared to be stronger type II
collagen neoepitope staining in the cartilage of heterozygous DMM animals than in that
of their knockout littermates or sham controls (Figure 4.3B).
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Figure 4.1 A schematic representation of the post-traumatic and spontaneous aging
models of OA used in this study. Ten-week old male Tgfa null and heterozygous mice
underwent destabilization of medial meniscus (DMM) surgery. Two post-surgical time
points were assessed with OARSI scoring: seven and fourteen weeks. Six-month-old Tgfa
null and heterozygous mice also underwent DMM surgery and were assessed seven
weeks post-surgery. Lastly, Tgfa null and heterozygous mice were housed for eighteen
months with no surgical intervention, after which time spontaneous disease progression
was assessed with OARSI scoring.
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Figure 4.1 A schematic representation of the post-traumatic and spontaneous aging
models of OA used in this study.
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Figure 4.2 Tgfa knockout mice have lower OARSI scores than control littermates in
a surgical model of OA. Ten-week-old Tgfa knockout mice and their heterozygous
littermates received either surgery resulting in the destabilization of the medial meniscus
(DMM) or sham surgery. At seven weeks post surgery, mice were sacrificed and their
knee joints were prepared for histology. Tissues were stained with safranin-O and fast
green (A) and then scored using the OARSI system for OA histopathology (B). Average
OARSI scores +SEM are shown and indicate that Tgfa knockout mice have lower scores
than OA heterozygous mice after DMM surgery (DMM groups n=5, sham groups n=4,
*p<0.05).
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Figure 4.2 Tgfa knockout mice have lower OARSI scores than control littermates in a
surgical model of OA.
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Figure 4.3 Tgfa knockout mice express less MMP13 and less type II collagen
neoepitopes than control littermates at 7 weeks post-surgery. Histological sections
were prepared from the knee joints of both Tgfa knockout and heterozygous mice at
seven weeks post-surgery. Immunohistochemistry was performed with primary
antibodies against MMP13 and type II collagen fragments. This was followed by
secondary antibody incubation and visualization with the substrate DAB (brown
precipitate). Nuclei were counterstained with hematoxylin (blue). Representative images
show that knockout animals express less MMP13 and type II collagen fragments than
heterozygous controls.
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Figure 4.3 Tgfa knockout mice express less MMP13 and less type II collagen
neoepitopes than control littermates at 7 weeks post surgery.
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Similar results were seen when mice were analyzed fourteen weeks after surgery;
heterozygous DMM animals had significantly higher scores (17.3) than knockout DMM
animals (10.2) (Figure 4.4B). Many more DMM animals displayed advanced disease
features such as superficial zone delamination and lesions extending into the midzone
(Figure 4.4A), and some heterozygous animals displayed lesions extending to the
calcified cartilage. Scores for both DMM groups were higher than at the seven week time
point, indicating that the disease had progressed, while both sham groups had scores
similar to those of the earlier time point (Figure 4.4B).
4.4.2

6-month-old Tgfa null mice are not protected from OA progression in a
DMM model

These results suggested that loss of TGFα signaling protects from post-traumatic OA in
young adults, a finding of significant impact for the human population because of the
high number of sports-related injuries in this age group. However, humans joint injuries
can also occur at later ages, thus combining two OA risk factors (aging and injury). To
address this point, we performed DMM and sham surgery on six-month-old mice. OA
progression was more advanced than when surgery was performed on younger mice
(Figure 4.5A). Both Tgfa knockout mice and their heterozygous littermates had average
OARSI scores of 17.1 when assessed at seven weeks post-surgery (Figure 4.5B). A
number of disease features were evident including proteoglycan loss, superficial zone
delamination and erosion of midzone cartilage (Figure 4.5A). In addition to the disease
features mentioned above, some six moth old tissues revealed denudation to the calcified
zone. Tgfa null mice were no longer protected from developing OA, since the knockout
mice had scores and histopathological features similar to those of the heterozygous mice
(Figure 4.5B).
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Figure 4.4 Tgfa knockout mice still show resistance to developing OA at 14 weeks
post-surgery. 10 week-old Tgfa knockout mice and their heterozygous littermates
received DMM surgery or sham surgery. At fourteen weeks post surgery, mice were
sacrificed and their knee joints were prepared for histology. Tissues were stained with
safranin-O and fast green (A) and then scored using the OARSI system for OA
histopathology (B). DMM knockout animals still displayed lower OARSI scores than
their heterozygous control littermates at this time point (DMM groups n=6, sham groups
n=4, *p<0.05).
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Figure 4.4 Tgfa knockout mice still show resistance to developing OA at 14 weeks post
surgery.
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Figure 4.5 There is no difference in disease progression between knockout and
control animals after DMM surgery in middle-aged mice. Six-month-old Tgfa
knockout and heterozygous mice received DMM or sham surgery. At seven weeks post
surgery, these mice were sacrificed and their knee joints were isolated and prepared for
OARSI scoring. Average OARSI scores +SEM are shown and indicate that DMM
knockout and heterozygous mice are equally susceptible to developing OA in this model
(sham groups n=4, DMM Het n=6, DMM KO n= 8, *p<0.05).
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Figure 4.5 There is no difference in disease progression between knockout and control
animals after DMM surgery in middle-aged mice.
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4.4.3

Tgfa null mice are not protected from developing spontaneous OA

To address a potential role of TGFα in aging-associated OA, the knee, elbow, and ankle
joints of eighteen-month-old mice were examined for spontaneous OA. Female mice
were essentially completely protected from developing OA (data not shown). This
finding has been well established in the literature and is attributed to difference in sex
hormones (29). The knee joints of male mice showed the most advanced disease of the
joints examined, revealing areas of proteoglycan loss, some areas of superficial zone
delamination, and some loss of the midzone cartilage. Regardless of the genotype,
however, articular cartilage remained largely intact, and areas of cartilage loss were focal
in nature (Figure 4.6A). The elbow and the ankle cartilage for both Tgfa null and
heterozygous mice was relatively healthy and showed only initial signs of OA,
particularly proteoglycan loss (Figure 4.6B,C). Essentially all of the tissues examined
from the elbow and the ankle had an intact articular cartilage surface, free of fibrillations
and fissures (Figure 4.6B,C).
4.5

Discussion

Previously, our lab identified TGFα as a novel growth factor involved in the
degeneration of articular cartilage (15, 16). In this study, we examined the role of TGFα
in the progression of OA in vivo through the use of the Tgfa null mouse. We analyzed
two separate models of OA: the post-traumatic DMM model as well as a spontaneous
model of OA in aging mice. When young adult, ten-week old Tgfa null mice received
DMM surgery, they were protected from developing OA at both post-surgical time points
examined. While they still showed signs of degeneration, particularly at the later time
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Figure 4.6 Tgfa knockout and heterozygous mice are equally susceptible to
developing OA in an aging disease model. Male Tgfa knockout and heterozygous mice
were housed until eighteen months of age. Animals were then sacrificed, and their knee
(A), elbow (B) and ankle (C) joints were prepared for histology. Tissues were stained
with safranin-O and fast green and scored using the OARSI recommendations for
histopathological assessment of OA in the mouse. There were no differences in OARSI
scores between genotypes for any of the joints examined (knee n=7, elbow n=4, ankle
n=4, p<0.05).
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Figure 4.6 Tgfa knockout and heterozygous mice are equally susceptible to developing
OA in an aging disease model.
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point (14 weeks after surgery), disease progression was histologically less severe than
that of control littermates. These data support our hypothesis, which is that in the absence
of TGFα, mice are protected from OA development in a post-traumatic model. Our
hypothesis was based on previous in vitro experiments that showed TGFα induced an
OA-like phenotype in articular chondrocytes (7), as well as our findings of upregulation
of Tgfa gene expression in a rat model of post-traumatic OA (4, 6). Specifically, TGFα
caused a decrease in expression of Sox9, aggrecan, and type II collagen mRNA, and
increased the expression of catabolic factors such as MMP13 (7). Thus by eliminating
TGFα, we expected that we could reduce these overall catabolic events.
Contrary to our hypothesis however, the Tgfa null mice were not protected from
developing OA in our spontaneous aging model or when DMM was performed in older
mice. As mentioned previously, several changes occur in aging cartilage that could
potentially make it more susceptible to injury, such as a more heavily cross-linked
extracellular matrix, a loss in aggrecan content, and chondrocytes that are less responsive
to anabolic factors (1). Furthermore, studies have shown that in the C56 BL/6 mouse
articular cartilage thickness decreases with age, chondrocyte death increases, and the
overall number of chondrocytes decreases as well (32). These changes within the tissue
provide one potential explanation for why our older Tgfa null mice were more susceptible
to or less protected from OA development. In addition to the articular cartilage itself,
changes within the broader context of the joint are seen with aging. A recent study by
Loeser et al. looked at the differences in gene expression within the entire joint in young
and old mice receiving either sham or DMM surgery (28). In this particular study, twelve
week old mice were used for the young group and twelve month old mice were used for
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the aged group (28). Interestingly, many genes were found to be dysregulated between
the young and aged groups post DMM surgery, as well as between the young and old
sham-operated mice (28). This study clearly illustrates baseline differences in gene
expression between joint tissues of young and old mice as well as differences in gene
expression changes in response joint injury (28). Novel genes, including some related to
muscle development and immune function, were identified thus highlighting the fact that
tissues beyond the articular cartilage itself are likely important in the disease process
(28). Since we did not specifically study other joint tissues (synovial membrane,
subchondral bone, or surrounding muscles), it is possible that changes in these structures
affected the overall function of the joint with age.
A study by Goekoop et al in 2005 examined a group of ninety-year-olds living without
OA and identified several protective factors including male sex, a normal body mass
index (BMI), and the absence of a family history of osteoarthritis (18). Obesity is a wellestablished risk factor for osteoarthritis, however its role in OA extends beyond
mechanical effects, and a vast body of research is now focused on the link between fat
metabolism and OA (15, 41). Furthermore, as people age, muscle mass generally declines
and fat content increases (12). The animals in our studies were weighed at the time of
surgery and sacrifice, however no differences were observed between the two genotypes
(data not shown). While BMI and fat composition were not assessed quantitatively, older
animals of both genotypes were observed to have more fat within their tissues upon
dissection. Thus, perhaps the lack of protection seen in older Tgfa knockout mice could
be attributed to changes relating to fat composition and metabolism.
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There is additional evidence to suggest that TGFα and its downstream signaling pathway
might be a good therapeutic target for OA therapy. TGFα is a member of the epidermal
growth factor (EGF) family and signals through the EGF receptor (EGFR) (11, 23, 24).
Recent studies have shown that mutant mice with enhanced EGFR signaling develop
early, spontaneous degenerative disease in multiple joints the including knee, ankle, and
temporomandibular joints (21, 50). These mice have a mutation in mitogen-inducible
gene 6 (MIG6), also known as RALT or Gene 33 (50). MIG6 is a cytoplasmic protein
that negatively regulates EGFR signaling through several mechanisms, including
inhibition of the receptor kinase domains and receptor internalization and degradation
(14, 19, 46, 48). These mutant mice have classical arthritic features such as loss of
proteoglycan content, degradation of articular cartilage, formation of subchondral cysts,
synovial hyperplasia, osteophyte formation, and abnormal calcification (21, 50). These
studies suggest that increased EGFR signaling is sufficient to trigger spontaneous disease
progression in vivo and consequently one might infer that blocking this signaling could
prevent or delay disease progression. One difference between the MIG6 studies and our
study is that in these models signaling from all EGFR ligands is inhibited while we
specifically targeted TGFα. Thus, compensation by other EGF family members is
another possible explanation for the lack of protection from OA in aging Tgfa null mice.
As well, we have recently described a transient developmental bone phenotype in our
Tgfa null mice that appears to resolve by ten weeks of age (the age that DMM surgeries
are performed in this study) (42). However, we cannot be certain that the effects of this
developmental phenotype, which include delayed osteoclast recruitment and decreased
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MMP13 and RANKL (receptor activator of nuclear factor kappa B ligand) gene
expression, do not have an effect on the outcome of our OA studies (42).
Our current results, however, suggest that targeting TGFα and its receptor might be
beneficial in a subset of patients, potentially younger patients who have experienced a
joint injury. It is possible that TGFα plays an important role post-trauma. We first
identified TGFα as a growth factor involved in cartilage degeneration in microarray
studies from another post-traumatic model of OA, namely the rat ACL transection/partial
meniscectomy model (6). Our previous in vitro studies showed that in addition to the loss
of chondrocyte phenotype, TGFα had an effect on chondrocyte proliferation both in
primary articular chondrocyte cell culture and in an articular cartilage organ culture
system (7). In the organ culture system, proliferation was evident based on the presence
of chondroyte clusters, a well-established sign of early OA, believed to represent an
attempt at cartilage repair (7, 40). Thus it is possible that TGFα is produced locally
within the joint in response to injury, but lacks to ability to successfully repair cartilage.
Our collaborators also examined TGFα mRNA in human cartilage collected at the time
of joint replacement (7). Five of twelve arthritic samples expressed markedly increased
TGFα mRNA levels, thus again suggesting that the growth factor plays an important role
in a subset of patients (7).
Overall it appears that TGFα plays an important role in post-traumatic OA progression.
Other factors, such as age however, also contribute to disease severity and progression. It
may be important to take factors such as age and mechanism of joint injury into account
when selecting patient for clinical trials for the development of DMOADs.
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Chapter 5
5

Discussion

5.1

Overview

The overall objective of my thesis was to gain a better understanding of the role of
transforming growth factor alpha (TGFα) in cartilage biology, both in the cartilage
growth plate during endochondral bone development and in degenerating articular
cartilage during the disease state of osteoarthritis (OA). My laboratory first became
interested in TGFα after my colleagues performed microarray studies on articular
cartilage isolated from a surgical rat model of OA (6, 7). TGFα mRNA levels were
elevated almost 4-fold in the OA animals compared controls (6). The laboratory decided
to pursue this growth factor further since its role in normal cartilage biology was not fully
understood and since it had not previously been implicated in OA initiation or
progression. Initial in vitro investigations showed that TGFα had a profound effect on the
chondrocyte phenotype: TGFα treatment caused changes in chondrocyte morphology,
induced proliferation, and shifted synthesis away from anabolic factor expression towards
that of catabolic factor expression (8). The next logical step was to investigate possible
downstream pathways that might regulate TGFα-induced effects on the chondrocyte
phenotype.
The first study in my thesis investigates the link between TGFα and the endothelin
receptor A (ET(A)R) signaling system. Just like TGFα, the gene for ET(A)R denoted as
Ednra, was upregulated in the original rat model of OA (6). There is also a body of
literature implicating ET(A)R in both OA and normal chondrocyte aging (30-34, 40, 45,
46, 51). Since age is one of the most common risk factors for OA, I decided that this
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would be a good downstream candidate target to focus on. Furthermore, ET(A)R is
known to interact with the receptor through which TGFα signals, the epidermal growth
factor receptor (EGFR), in other diseases such as cancer (10, 37). I subsequently
performed in vitro experiments with primary chondrocyte cell cultures and osteochondral
organ culture explants. I found that TGFα induced ET(A)R expression at both the mRNA
and protein level. However, inhibiting ET(A)R with a non-specific ET(A/B)R antagonist
only partially blocked the TGFα effects in our explant model. Thus while ET(A)R
appears to be a downstream target of TGFα, the signaling pathways affected by this
growth factor are clearly more complex.
Next I wanted to examine TGFα function in the skeleton using an in vivo system.
Therefore the third and fourth chapters of this thesis involve the Tgfa knockout mouse
previously characterized by Mann et al. (41). The major phenotype reported in this mouse
is the presence of a wavy coat due to the misalignment of hair follicles (41). No mention
of bone or cartilage abnormalities is made. Previous in vitro literature, on the other hand,
does suggest a role for TGFα in bone development and turnover. Studies indicate that
TGFα has a negative effect on chondrogenesis of limb bud mesenchymal cells (14, 23,
64). As well, research has shown that TGFα stimulates bone resorption and inhibits bone
formation in vitro (25, 26). The role of TGFα during endochondral bone development has
not been explicitly examined however, and this led me to my second major study.
I examined the cartilage growth plates of Tgfa wildtype, heterozygous, and null mice
over a variety of time points ranging from newborn to ten weeks of age. Interestingly,
Tgfa null mice were found to have a transient growth plate phenotype characterized by an
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enlarged hypertrophic zone and decreased numbers of osteoclasts at the cartilage/bone
interface. Analysis of gene expression revealed that these mice also express less matrix
metalloproteinase 13 (MMP13) as well as less receptor activator of nuclear factor kappaB ligand (RANKL) mRNA than their heterozygous and wild type littermates. RANKL is
an important activator of osteoclastogenesis and chondrocyte-produced RANKL has been
shown to stimulate osteoclast formation (35, 57). MMP13 also plays an important role in
extracellular matrix breakdown during endochondral bone formation, and is required for
normal vascularization and subsequent bone remodeling (27, 56). Thus I demonstrated a
previously unrecognized growth plate phenotype in the Tgfa knockout mouse and
reported TGFα’s regulatory role in the transition from cartilage to bone.
Lastly, I wanted to examine the role of TGFα in the disease state of osteoarthritis in vivo.
I used the well-established destabilization of medial meniscus model (DMM) to represent
a slowly progressing model of post-traumatic OA (19). Furthermore, I examined
spontaneous disease progression in aging animals. Due to the overall catabolic effect of
TGFα in articular chondrocytes and cartilage explants in vitro, I hypothesized that Tgfa
null mice would be protected from OA progression in both the injury and aging models.
I found that young knockout mice were protected in the DMM model, however aging
knockout mice developing spontaneous disease as well as older knockout mice receiving
DMM surgery were not protected from OA progression. This study demonstrates that
TGFα may be an important therapeutic target in post-traumatic forms of OA, however its
role may not be as significant when other risk factors such as age come into play. This
study also reminds us that OA is a complex multifactorial disease and that treatments
may need to be specific to the main etiological risk factors involved.
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Overall, these data demonstrate an important role for TGFα both in the conversion of
cartilage to bone during endochondral ossification, and in cartilage degeneration in
osteoarthritis. A common thread between development and disease, is that both of these
mechanisms appear to be driven in part through the production of catabolic factors such
as MMP13.
5.2
5.2.1

Contributions and Significance of Findings
Contributions to the Field of Skeletal Biology

In this thesis, I characterize for the first time the growth plate phenotype of TGFα null
mice. Prior to these studies, the role of TGFα in the cartilage growth plate had not been
explicitly investigated. As mentioned above however, previous work did highlight
TGFα’s negative effect on chondrogenesis and its stimulatory effect on
osteoclastogenesis (14, 23, 25, 26, 64). I describe the transient growth plate phenotype of
Tgfa null mice that includes shorter tibiae and humeri, an enlarged hypertrophic zone and
overall growth plate length, delayed primary and secondary ossification, and reduced
osteoclast staining at the cartilage/bone junction. To complement the decrease in
osteoclasts, I also demonstrate a decrease in Mmp13 and Rankl gene expression. The
phenotype seen is very similar to that of the Efgr knockout mouse (61). Since these mice
do not survive long after birth, they were consequently studied during embryonic
development only. Their growth plate phenotype, however, is very similar to that seen in
my studies and is characterized by delayed primary ossification, an enlarged hypertrophic
zone, and decreased osteoclast recruitment (61). This study examined the inactivation of
the EGF receptor and thus the identity of the ligand or ligands involved remained
unknown. The bone phenotypes of other EGFR ligand knockout mice have been
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characterized, including amphiregulin (AREG) and betacellulin (BTC) (52). Neither of
these models however, has reported a growth plate phenotype as seen in the Egfr
knockout mouse. Thus it is likely that TGFα is one of the main ligands responsible for
the roles of EGFR during endochondral ossification. In addition, my studies provide
mechanistic insights into the observed phenotype, namely through the reduced expression
of MMP13 and RANKL in cartilage of Tgfa null mice.
My collaborators recently published a study exploring the inactivation of EGFR at postnatal time points in the rat through the use of an EGFR specific inhibitor, gefitinib (66).
Their study complements the Tgfa knockout model in that the gefitinib-treated rats
developed an expanded cartilage growth plate with an accumulation of hypertrophic cells,
and had decreased osteoclasts at the osteochondral junction (66). The rats also expressed
less Rankl and Mmp13 than untreated animals (66). To determine whether these effects
were due to primary effects on the growth plate, my collaborators also created cartilagespecific Egfr knockout mice using the Col2a1-promoter to drive Cre recombinase
expression (66). Again, similar changes in the growth plate were observed, thus
revealing that EGFR inactivation directly affects the cartilage growth plate. The overlap
observed between the TGFα knockout mouse and models of EGFR inactivation further
suggests that TGFα is the main mediator of EGFR effects in the cartilage growth plate.
In addition to these findings, I implicate TGFα in the development of the secondary
ossification centre for the first time. Tgfa null mice show delay in secondary ossification
when compared to their control littermates. When I performed immunohistochemistry
(IHC) in the secondary ossification centre with an antibody specific for the blood vessel
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marker platelet endothelial cell adhesion molecule 1 (PECAM-1), I saw reduced levels of
staining in the mutant animals. Thus in addition to its role in the primary ossification
centre, I have demonstrated a role for TGFα in secondary ossification development.
Lastly, through in vivo embryonic tibia organ culture studies, I show that TGFα affects
genes related to chondrocyte hypertrophy. Specifically, TGFα decreases expression of
early hypertrophic markers including p57 and ColX, and increases the expression of late
hypertrophic markers including the Mmp9, Mmp13, and Mmp14. These results suggest a
novel role for TGFα in promoting the transition from early hypertrophic to terminally
differentiated chondrocytes. Collectively these data contribute to the growing
understanding of molecular mechanisms controlling the organization and regulation of
the cartilage growth plate. They also give us insight into how TGFα might contribute to
cartilage pathology in osteoarthritis, namely through catabolic factor expression and
potentially through other mechanisms such as chondrocyte hypertrophy.
5.2.2

Contributions to Field of Osteoarthritis

I demonstrate that ET(A)R is a downstream target of TGFα. Furthermore I demonstrate
this in two different species (rat and mouse) and in tissues of varying ages (embryonic,
newborn, and four to five month old tissues). My in vitro experiments show that TGFα
upregulates ET(A)R in articular chondrocytes at both the mRNA and protein level. This
is consistent with previous work, demonstrating that a number of growth factors and
cytokines including EGF are able to induce ET(A)R expression in articular chondrocytes
(46). Inhibiting endothelin signaling with a non-specific ET(A/B)R inhibitor however,
only partially blocks TGFα catabolic effects in articular cartilage, namely the expression
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of MMP13 and subsequent breakdown of type II collagen. Thus there must be other
signaling pathways downstream of TGFα capable of mediating its OA-like phenotype.
Additional work done in my lab demonstrates that various pathways are responsible for
mediating TGFα effects in articular chondrocytes. For example, RhoA/ROCK has been
shown to mediate TGFα -induced morphologic changes in chondrocytes, in agreement
with previous studies demonstrating important roles of this pathway in chondrogenesis
(60, 62). The MEK/ERK pathway mediates the downregulation of anabolic gene
expression by TGFα, again fitting with known roles of this pathway in chondrocytes (11,
55). Both the Rho/ROCK and MEK/ ERK pathway also regulate type II collagen
cleavage and aggrecan breakdown in articular cartilage (9). Thus while TGFα is capable
of inducing ET(A)R expression in articular chondrocytes, this is only one signaling
pathway of many involved in the induction of an OA-like phenotype.
In addition, I also show an increase in inducible nitric oxide synthase (iNOS) staining in
IHCs from the TGFα- treated organ culture studies. To my knowledge, this is the first
time that TGFα has been shown to effect parameters of nitric oxide (NO) metabolism in
articular chondrocytes. This is significant as the increase in iNOS may contribute to NO
production and potentially serve as another mechanism through which TGFα carries out
its catabolic effects (5, 47, 58). Recently, a study by Kaufman et al complemented my
ET(A)R studies nicely (29). This group demonstrated that inhibition of the ET(A)R with
a specific inhibitor (BQ-123) in a surgical model of OA prevented disease progression. A
similar model of OA was used (rat ACL transection) as in my laboratory’s original
studies (6, 7).
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My in vivo models of OA also provide novel information to the field. I demonstrate that
young adult Tgfa null mice are protected from developing OA in a DMM model of the
disease, both at seven and fourteen weeks post-surgery. Through this in vivo model, I
have validated TGFα as a potential therapeutic target for the development of a disease
modifying osteoarthritic drug (DMOAD). Experts in the field support the use of in vivo
surgical disease models to validate potential therapeutic OA targets (17). For example,
DMM surgery was performed in the ADAMTS-5 (a disintegrin and metalloproteinase
with thrombospondin motifs) knockout mouse, and observations of delayed disease
progression now make it one of the most attractive targets for DMOAD development (18,
48).
Prior to the microarray studies, TGFα had not been implicated in the disease process.
Previous research did however, report the presence of TGFα in the synovial fluid and
synovial membranes of arthritic patients with higher levels observed in individuals with
rheumatoid arthritis (RA) than in those with OA (22, 36). TGFα has also been detected in
control synovium and synovial fluid, suggesting a normal physiological role within the
joint (22). Evidence does exist however, for the involvement of EGFR in OA
development. Recent studies involving mice with mutations in mitogen-inducible gene 6
(MIG6) have reported spontaneous degenerative joint disease in these animals (67).
MIG6 (also known as RALT or Gene 33) is a cytoplasmic protein that negatively
regulates EGFR signaling by several mechanisms (16, 21, 63, 65). Homozygous null
mutants of the Mig6 allele develop early degenerative disease in the knee, ankle, and
temporomandibular joints (28, 67). As well, the Mig6 null joints show classical arthritic
features including depletion of proteoglycans, degradation of articular cartilage,

164

formation of subchondral cysts, synovial hyperplasia, osteophyte formation, and
abnormal calcification (28, 67). These studies illustrate that enhanced EGFR signaling is
sufficient to trigger spontaneous disease progression in vivo and thus complement my
knockout studies, in which decreased EGFR ligand is protective.
My studies also reveal that the protection from OA is not universal in all osteoarthritic
models. In the aging models (spontaneous OA development and DMM surgery
performed in older mice) the Tgfa knockout mice are no longer protected from disease
progression, and they develop OA that is histologically indistinguishable from control
mice. Age is a major risk factor for the development of OA, and specifically with
meniscal injuries, it has been shown that the tempo of disease progression varies with age
(44, 50). Patients who sustain a meniscal injury between the ages of seventeen and thirty
develop radiologic signs of OA on average after fifteen years, while patients who sustain
the same injury over the age of thirty develop signs of OA only five years later (50). Our
data fit with this clinical picture as the aging mice show more aggressive lesions postsurgery, and all aging mice regardless of genotype are susceptible to disease progression.
These data also contribute to the theory that OA is a heterogeneous disease based on
specific etiological risk factors (i.e. obesity, aging, injury) and that DMOADs should be
developed with these sub-phenotypes of OA in mind (12). In the case of TGFα, the
evidence thus far suggests that it might be an important therapeutic target in posttraumatic cases of OA in young individuals.
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5.3
5.3.1

Limitations of Research
Limitations of In Vitro Models

I acknowledge that these studies have several limiting factors. Firstly, my in vitro
experiments are clearly limited by their ability to recapitulate the in vivo environment.
For the ET(A)R studies I used both primary chondrocyte cultures and osteochondral
explant cultures. The primary chondrocyte cultures were isolated from the distal femoral
condyles of neonatal rats and plated in monolayer culture as previously described (53).
The benefit of this culture system is that a large number of cells can be isolated at once;
chondrocyte isolation would be far more challenging from mature articular cartilage with
sparse cellular density. However, the major drawback is that these cells are very young,
and as previous stated, differences in gene expression, responses to growth factors, and
receptor profiles are seen with aging chondrocytes (38, 45, 46). This culture system may
not have been the best choice for my ET(A)R studies as the receptor density is known to
increase significantly with aging chondrocytes (45, 46). Furthermore, monolayer cultures
lack interaction with an extracellular matrix. Consequently, cell surface receptors such as
integrins that would normally interact with the matrix, likely have altered signaling in this
context (20).
The osteochondral explants address some of these limitations (i.e. they are derived from
adult animals and retain an intact extracellular matrix), but they still lack the influence of
mechanical forces. Chondrocytes are known to response to various forces through
integrin receptors, stretch-activated calcium ion channels, and deformation of the
chondrocyte cytoskeleton (2, 4, 13, 20). Lastly, these in vitro models lacked the context
of the joint as a unit. It is well established that OA is a disease affecting the entire joint
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including the articular cartilage, synovial membrane, joint capsule, and subchondral bone
(3, 24). By examining effects on articular chondrocytes or cartilage alone we lose
potentially important cross-talk between these tissues. Future in vivo studies using
pharmacological or genetic manipulation of the ET(A)R signaling system would
complement our studies, but as outlined, some of these have been performed by others
recently (29).
The non-specific ET(A/B)R inhibitor Bosentan that was used in my studies also provides
some concerns. Bosentan is a dual endothelin receptor A/B antagonist which is clinically
used for the treatment of pulmonary arterial hypertension (43). We chose to use this drug
since it has already been approved for use clinically. However, the antagonist is not
selective for ET(A)R and thus it is possible that some of the effects we saw in
chondrocyte cell culture and organ culture were due to inactivation of ET(B)R and its
downstream pathways. Use of receptor-specific antagonists such as BQ-123 would be
one potential future application.
5.3.2

Limitations of In Vivo Models

In my growth plate studies, RNA was isolated from newborn (P0) mice since cartilage is
expansive and easily accessible at this stage. It is difficult to distinguish the growth plate
cartilage from what will become the articular cartilage at this stage since the secondary
ossification centre (which divides these two regions) has not yet developed. While the
mutant phenotype is predominantly present in the hypertrophic zone of the growth plate, I
decided to take all cartilage from P0 tibia since it is plausible that factors regulating this
phenotype may come from other areas of the growth plate or other chondrocytes in
general. It is possible that some areas of the growth plate might have been missed during
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isolation, especially some of the cartilage adjacent to the mineralized zone. Furthermore,
it is possible that other tissues such as perichondrium were isolated along with the
cartilage. I did my best to remove all excess tissues and collect the complete growth
plate, however it is possible that some of the gene changes we observed were in part due
to additional tissues.
I used full body Tgfa knockout mice in my experiments, in which the Tgfa allele was
disrupted by the insertion of a neomycin cassette (41). Since I did not use a tissuespecific knockout model, I cannot be completely confident that the developmental
phenotype I have characterized is due to direct effects of the absence TGFα of on the
growth plate. Rather, it is possible that these effects are mediated by some other systemic
factors influenced by the null mutation. My collaborators however, have created a
cartilage-specific Egfr knockout mouse that has a similar phenotype to the Tgfa null
mice, thus suggesting that my observations may indeed be due to direct effects (66).
Furthermore, while I describe a transient developmental phenotype in these mice that
resolves by ten weeks of age, I cannot be absolutely certain that this phenotype does not
in some way persist or affect the OA studies. My conclusion that TGFα is a novel
therapeutic DMOAD target, assumes that the developmental phenotype does not in some
way affect OA susceptibility in our knockout animals. In other words, unlike a drug that
could be administered to patients at the time of joint injury, our mice have always had
their mutation, and this fact may affect the clinical relevance of our study.
My collaborators (Qin and colleagues, University of Pennsylvania) performed micro CT
analysis on aging animals and found that the Tgfa null skeleton appears to lose both
cortical area and trabecular volume over time (data not shown). I need to perform more
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studies to correctly interpret these results, however it is evident that there are still some
effects of the Tgfa mutation even in mice older than ten weeks of age.
The DMM surgery provides a mild model of post-traumatic OA (19). It is relevant as
meniscal injuries are almost always seen with radiographic signs of OA, and as the
meniscus is the most commonly injured intra-articular tissue (15, 39). I also employed an
aging model of OA by analyzing spontaneous joint disease. While I limited my analysis
to these two models, there are numerous additional risk factors that contribute to OA
including obesity, female gender, and repetitive mechanical loading. From this thesis, my
interpretations are limited to the role of TGFα in post-traumatic OA and aging as I did
not take these other factors into account. Currently however, some of my colleagues are
investigating the effects of a high fat diet on joint pathology in various genetically
modified mice, including the Tgfa mutants.
5.4

Future Directions

Several possible future projects could be explored based on the results of this thesis.
Firstly, to confirm both the Tgfa null growth plate phenotype and the results from our OA
models, it would be useful to create a cartilage-specific Tgfa knockout mouse using the
Cre-loxP system with Cre recombinase expressed under control of the Col2a1 promoter,
as our laboratory has done for other genes (54, 59). In addition, it would be beneficial to
examine multiple joint tissues including the subchondral bone, synovium, and synovial
fluid. By examining the entire joint, one may gain a better understanding of how these
tissues interact and signal to each other throughout disease progression. Furthermore, I
could add gait analysis to these studies to assess joint function. Thus far I have been
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focusing on cartilage damage as the main endpoint. However structural changes alone are
not sufficient for a clinical diagnosis of the OA.
It might also be worthwhile to create an inducible, tissue-specific ET(A)R knockout
mouse. Full body ET(A)R knockout mice do not survive long after birth due to
respiratory distress and they also display craniofacial abnormalities (1). While another
group has already demonstrated that OA progression can be delayed in an ACL
transection model of OA with ET(A)R inhibition, it might be of value to determine
whether knocking out this receptor later in life prevents spontaneous disease progression.
This would be particularly interesting since ET(A)R expression in chondrocytes appears
to increase with age (45, 46).
Lastly, it would be very interesting to explore the role of TGFα in other forms of joint
disease such as RA. As previously mentioned, TGFα has been identified in synovial fluid
and synovial membranes of both OA and RA patients, and higher levels were actually
observed in individuals with RA (22, 36). Furthermore, studies have shown that bone
destruction in RA may be mediated by osteoclasts, and that chondrocyte-produced
RANKL may contribute to the activation of cells and subsequent juxta-articular bone loss
(42, 49). These findings suggest that TGFα could affect RA and possibly OA through
effects on osteoclasts.
5.5
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Appendices
Appendix A: Animal Protocols

AUP Number: 2007-003-02
PI Name: Beier, Frank
AUP Title: Tgfα/egfr Signaling In Osteoarthritis
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use
Protocol (AUP) entitled "Tgfα/egfr Signaling In Osteoarthritis" has been APPROVED by
the Animal Use Subcommittee of the University Council on Animal Care. This approval,
although valid for four years, and is subject to annual Protocol Renewal.2007-003-02::5
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the
ACVS office. Health certificates will be required.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
Submitted by: Copeman, Laura
on behalf of the Animal Use Subcommittee
University Council on Animal Care
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AUP Number: 2007-045-06
PI Name: Beier, Frank
AUP Title: Regulation Of Endochondral Bone Growth By Hormones
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use Protocol (AUP)
entitled "Regulation Of Endochondral Bone Growth By Hormones
" has been APPROVED by the Animal Use Subcommittee of the University Council on Animal Care. This
approval, although valid for four years, and is subject to annual Protocol Renewal.2007-045-06::5
1.
2.
3.

This AUP number must be indicated when ordering animals for this project.
Animals for other projects may not be ordered under this AUP number.
Purchases of animals other than through this system must be cleared through the ACVS office.
Health certificates will be required.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have
received all necessary approvals. Please consult directly with your institutional safety officers.
Submitted by: Copeman, Laura
on behalf of the Animal Use Subcommittee
University Council on Animal Care
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